<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        7-5518-22
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FORXIGA 10 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DAPAGLIFLOZIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        159
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AstraZeneca Pharmaceuticals LP" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AstraZeneca Pharmaceuticals LP
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AstraZeneca AB 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BX09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>What Forxiga is</strong></p><p dir="ltr">Forxiga contains the active substance dapagliflozin. It belongs to a group of medicines called &ldquo;sodium glucose co-transporter-2 (SGLT2) inhibitors&rdquo;. They work by blocking the SGLT2 protein in your kidney. By blocking this protein, blood sugar (glucose), salt (sodium) and water are removed from your body via the urine.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>What Forxiga is used for</strong></p><p dir="ltr">Forxiga is used in adult patients (aged 18 years and older) to treat:</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Type 2 diabetes</strong></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your type&nbsp;2 diabetes cannot be controlled with diet and exercise.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Forxiga can be used on its own or together with other medicines to treat diabetes.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is important to continue to follow the advice on diet and exercise given to you by your doctor, pharmacist or nurse.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Heart failure</strong></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in adults (aged 18&nbsp;years and older) when the heart does not pump blood as well as it should.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Chronic kidney disease</strong></p><p dir="ltr">-&nbsp; in adults with reduced kidney function.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>What is type 2 diabetes and how does Forxiga help?</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In type&nbsp;2 diabetes your body does not make enough insulin or is not able to use the insulin it makes properly. This leads to a high level of sugar in your blood. This can lead to serious problems like heart or kidney disease, blindness, and poor circulation in your arms and legs.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Forxiga works by removing excess sugar from your body. It can also help prevent heart disease.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>What is heart failure and how does Forxiga help?</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This type of heart failure occurs when the heart does not pump blood to the lungs and the rest of the body as well as it should. This can lead to serious medical problems and need for hospital care.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The most common symptoms of heart failure are feeling breathless, feeling tired or very tired all the time, and ankle swelling.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Forxiga helps protect your heart from getting worse and improves your symptoms. It can lower the need to go to hospital and can help some patients to live longer.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>What is chronic kidney disease and how does Forxiga help?</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When you have chronic kidney disease, your kidneys may gradually lose their function. This means they would not be able to clean and filter your blood the way they should. Loss of kidney function can lead to serious medical problems and need for hospital care.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Forxiga helps protect your kidneys from losing their function. That can help some patients to live longer.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not take Forxiga</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to dapagliflozin or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Warnings and precautions</strong></p><p dir="ltr"><strong>Contact a doctor or the nearest hospital straight away</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">Diabetic ketoacidosis:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have diabetes and experience feeling sick or being sick, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to your breath, a sweet or metallic taste in your mouth, or a different odour to your urine or sweat or rapid weight loss.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The above symptoms could be a sign of &ldquo;diabetic ketoacidosis&rdquo; &ndash; a rare but serious, sometimes life-threatening problem you can get with diabetes because of increased levels of &ldquo;ketone bodies&rdquo; in your urine or blood, seen in tests.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The risk of developing diabetic ketoacidosis may be increased with prolonged fasting, excessive alcohol consumption, dehydration, sudden reductions in insulin dose, or a higher need of insulin due to major surgery or serious illness.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When you are treated with Forxiga, diabetic ketoacidosis can occur even if your blood sugar is normal.</p><p dir="ltr">If you suspect you have diabetic ketoacidosis, contact a doctor or the nearest hospital straight away and do not take this medicine.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Necrotising fasciitis of the perineum:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor immediately if you develop a combination of symptoms of pain, tenderness, redness, or swelling of the genitals or the area between the genitals and the anus with fever or feeling generally unwell. These symptoms could be a sign of a rare but serious or even life-threatening infection, called necrotising fasciitis of the perineum or Fournier&rsquo;s gangrene which destroys the tissue under the skin. Fournier&rsquo;s gangrene has to be treated immediately.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Talk to your doctor, pharmacist or nurse before taking Forxiga</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have &ldquo;type&nbsp;1 diabetes&rdquo; &ndash; the type that usually starts when you are young, and your body does not produce any insulin.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes and have a kidney problem &ndash; your doctor may ask you to take additional or a different medicine to control your blood sugar.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a liver problem &ndash; your doctor may start you on a lower dose.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are on medicines to lower your blood pressure (anti-hypertensives) and have a history of low blood pressure (hypotension). More information is given below under &lsquo;Other medicines and Forxiga&rsquo;.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have very high levels of sugar in your blood which may make you dehydrated (lose too much body fluid). Possible signs of dehydration are listed in section&nbsp;4. Tell your doctor before you start taking Forxiga if you have any of these signs.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have or develop nausea (feeling sick), vomiting or fever or if you are not able to eat or drink. These conditions can cause dehydration. Your doctor may ask you to stop taking Forxiga until you recover to prevent dehydration.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you often get infections of the urinary tract.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If any of the above applies to you (or you are not sure), talk to your doctor, pharmacist or nurse before taking Forxiga.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Diabetes and foot care</strong></p><p dir="ltr">If you have diabetes, it is important to check your feet regularly and adhere to any other advice regarding foot care given by your health care professional.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Urine glucose</strong></p><p dir="ltr">Because of how Forxiga works, your urine will test positive for sugar while you are on this medicine.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Children and adolescents</strong></p><p dir="ltr">Forxiga is not recommended for children and adolescents under 18 years of age, because it has not</p><p dir="ltr">been studied in these patients</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Other medicines and Forxiga</strong></p><p dir="ltr">Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.</p><p dir="ltr">Especially tell your doctor:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking a medicine used to remove water from the body (diuretic).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking other medicines that lower the amount of sugar in your blood such as insulin or a &ldquo;sulphonylurea&rdquo; medicine. Your doctor may want to lower the dose of these other medicines, to prevent you from getting low blood sugar levels (hypoglycaemia).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking lithium because Forxiga can lower the amount of lithium in your blood.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Pregnancy and breast-feeding</strong></p><p dir="ltr">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should stop taking this medicine if you become pregnant, since it is not recommended during the second and third trimesters of pregnancy. Talk to your doctor about the best way to control your blood sugar while you are pregnant.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Talk to your doctor if you would like to or are breast-feeding before taking this medicine. Do not use Forxiga if you are breast-feeding. It is not known if this medicine passes into human breast milk.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Driving and using machines</strong></p><p dir="ltr">Forxiga has no or negligible influence on the ability to drive and use machines.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Taking this medicine with other medicines called sulphonylureas or with insulin can cause too low blood sugar levels (hypoglycaemia), which may cause symptoms such as shaking, sweating and change in vision, and may affect your ability to drive and use machines.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not drive or use any tools or machines, if you feel dizzy taking Forxiga.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Forxiga contains lactose</strong></p><p dir="ltr">Forxiga contains lactose (milk sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take this medicine exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>How much to take</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is one 10&nbsp;mg tablet each day.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may start you on a 5&nbsp;mg dose if you have a liver problem.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will prescribe the strength that is right for you.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Taking this medicine</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablet whole with half a glass of water.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take your tablet with or without food.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take the tablet at any time of the day. However, try to take it at the same time each day. This will help you to remember to take it.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Your doctor may prescribe Forxiga together with other medicine(s). Remember to take these other medicine(s) as your doctor has told you. This will help get the best results for your health.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Diet and exercise can help your body use its blood sugar better. If you have diabetes, it is important to stay on any diet and exercise program recommended by your doctor while taking Forxiga.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you take more Forxiga than you should</strong></p><p dir="ltr">If you take more Forxiga tablets than you should, talk to a doctor or go to a hospital immediately. Take the medicine pack with you.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you forget to take Forxiga</strong></p><p dir="ltr">What to do if you forget to take a tablet depends on how long it is until your next dose.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If it is 12&nbsp;hours or more until your next dose, take a dose of Forxiga as soon as you remember. Then take your next dose at the usual time.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If it is less than 12&nbsp;hours until your next dose, skip the missed dose. Then take your next dose at the usual time.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose of Forxiga to make up for a forgotten dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you stop taking </strong><strong>Forxiga</strong></p><p dir="ltr">Do not stop taking Forxiga without talking to your doctor first. If you have diabetes, your blood sugar may increase without this medicine.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Contact a doctor or the nearest hospital straight away if you have any of the following side effects:</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>angioedema, </strong>seen very rarely (may affect up to 1 in 10,000 people).</p><p dir="ltr">These are signs of angioedema:</p><p dir="ltr">- swelling of the face, tongue or throat</p><p dir="ltr">- difficulties swallowing</p><p dir="ltr">- hives and breathing problems</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>diabetic ketoacidosis</strong> - this is rare in patients with type&nbsp;2 diabetes (may affect up to 1 in 1,000&nbsp;people).</p><p dir="ltr">These are the signs of diabetic ketoacidosis (see also section 2 Warnings and precautions):</p><p dir="ltr">- increased levels of &ldquo;ketone bodies&rdquo; in your urine or blood</p><p dir="ltr">- feeling sick or being sick</p><p dir="ltr">- stomach pain</p><p dir="ltr">- excessive thirst</p><p dir="ltr">- fast and deep breathing</p><p dir="ltr">- confusion</p><p dir="ltr">- unusual sleepiness or tiredness</p><p dir="ltr">- a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat</p><p dir="ltr">- rapid weight loss.</p><p dir="ltr">This may occur regardless of blood sugar level. Your doctor may decide to temporarily or permanently stop your treatment with Forxiga.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>necrotising fasciitis of the perineum</strong> or Fournier&rsquo;s gangrene, a serious soft tissue infection of the genitals or the area between the genitals and the anus, seen very rarely.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Stop taking Forxiga and see a doctor as soon as possible if you notice any of the following serious side effects:</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>urinary tract infection,</strong> seen commonly (may affect up to 1 in 10&nbsp;people).</p><p dir="ltr">These are signs of a severe infection of the urinary tract:</p><p dir="ltr">- fever and/or chills</p><p dir="ltr">- burning sensation when passing water (urinating)</p><p dir="ltr">- pain in your back or side.</p><p dir="ltr">Although uncommon, if you see blood in your urine, tell your doctor immediately.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Contact your doctor as soon as possible if you have any of the following side effects:</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>low blood sugar levels</strong> (hypoglycaemia), seen very commonly (may affect more than 1 in 10&nbsp;people) in patients with diabetes taking this medicine with a sulphonylurea or insulin.</p><p dir="ltr">These are the signs of low blood sugar:</p><p dir="ltr">- shaking, sweating, feeling very anxious, fast heart beat</p><p dir="ltr">- feeling hungry, headache, change in vision</p><p dir="ltr">- a change in your mood or feeling confused.</p><p dir="ltr">Your doctor will tell you how to treat low blood sugar levels and what to do if you get any of the signs above.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Other side effects when taking Forxiga:</strong></p><p dir="ltr">Common</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; genital infection (thrush) of your penis or vagina (signs may include irritation, itching, unusual discharge or odour)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back pain</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; passing more water (urine) than usual or needing to pass water more often</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in the amount of cholesterol or fats in your blood (shown in tests)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increases in the amount of red blood cells in your blood (shown in tests)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreases in creatinine renal clearance (shown in tests) in the beginning of treatment</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p dir="ltr">&nbsp;</p><p dir="ltr">Uncommon (may affect up to 1 in 100 people)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of too much fluid from your body (dehydration, signs may include very dry or sticky mouth, passing little or no urine or fast heartbeat)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thirst</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; awakening from sleep at night to pass urine</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight decreased</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increases in creatinine (shown in laboratory blood tests) in the beginning of treatment</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increases in urea (shown in laboratory blood tests)</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>What Forxiga contains</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is dapagliflozin.</p><p dir="ltr">Each Forxiga 5&nbsp;mg film-coated tablet (tablet) contains dapagliflozin propanediol monohydrate equivalent to 5&nbsp;mg dapagliflozin.</p><p dir="ltr">Each Forxiga&nbsp;10&nbsp;mg film-coated tablet (tablet) contains dapagliflozin&nbsp;propanediol&nbsp;monohydrate equivalent to 10&nbsp;mg&nbsp;dapagliflozin.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tablet core: microcrystalline cellulose (E460i), lactose (see section&nbsp;2 &lsquo;Forxiga contains lactose&rsquo;), crospovidone (E1202), silicon dioxide (E551), magnesium stearate (E470b).</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; film-coating: polyvinyl alcohol (E1203), titanium dioxide (E171), macrogol&nbsp;3350 (E1521), talc (E553b), yellow iron oxide (E172).</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul dir="ltr"><li><p><strong>What Forxiga looks like and contents of the pack</strong></p><p>Forxiga 5&nbsp;mg film-coated tablets are yellow and round with diameter of 0.7&nbsp;cm. They have &ldquo;5&rdquo; on one side and &ldquo;1427&rdquo; on the other side.</p><p>Forxiga&nbsp;10&nbsp;mg film-coated tablets are yellow and diamond-shaped approximately 1.1&nbsp;x&nbsp;0.8&nbsp;cm diagonally. They have &ldquo;10&rdquo; on one side and &ldquo;1428&rdquo; on the other side.</p><p>&nbsp;</p><p>Forxiga 5&nbsp;mg tablets are available in aluminium blisters in pack sizes of 14, 28 or 98&nbsp;film-coated tablets in non-perforated calendar blisters and 30x1 or 90x1 film-coated tablets in perforated unit dose blisters.</p><p>Forxiga&nbsp;10&nbsp;mg tablets are available in aluminium blisters in pack sizes of 10 film-coated tablets in non-perforated blisters, 14, 28 or 98&nbsp;film‑coated tablets in non‑perforated calendar blisters and 30x1 or 90x1&nbsp;film‑coated tablets in perforated unit dose blisters.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                •	Forxiga 5 mg film coated tablets are yellow and round with diameter of 0.7 cm. They have “5” on one side and “1427” on the other side.
•	Forxiga 10 mg film coated tablets are yellow and diamond shaped approximately 1.1 x 0.8 cm diagonally. They have “10” on one side and “1428” on the other side.

Forxiga 5 mg tablets and Forxiga 10 mg tablets are available in aluminum blisters in pack size of 28 film coated tablets in non perforated calendar blisters.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Marketing Authorisation Holder</strong></p><p dir="ltr">AstraZeneca UK Limited,</p><p dir="ltr">600 Capability Green,</p><p dir="ltr">Luton,</p><p dir="ltr">LU1 3LU,</p><p dir="ltr">UK.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Manufacturer</strong></p><p dir="ltr">AstraZeneca UK Limited<br />Silk Road Business Park</p><p dir="ltr">Macclesfield</p><p dir="ltr">SK10 2NA</p><p dir="ltr">United Kingdom</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Jan 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ما هو عقار فورسيجا :</p><p dir="RTL">يحتوي فورسيجا على مادة فعالة اسمها داباجليفلوزين ، وهي تنتمي إلى مجموعة من الأدوية تسمى &quot;مثبطات الناقل المشترك-2 للغلوكوز والصوديوم( SGLT2)&quot;. ويُحقق هذا الدواء أثره عن طريق إحصار بروتين SGLT2 في الكُلى، وبذلك يتخلص الجسم من سكر الدم (الغلوكوز) والملح (الصوديوم) والماء عن طريق البول .</p><p>&nbsp;</p><p dir="RTL">دواعي استعمال فورسيجا يُوصف فورسيجا للمرضى البالغين (أي لا تقل أعمارهم عن 18 عاماً) لعلاج:</p><p>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض السكري من النوع الثاني</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة تعذر السيطرة على مرض السكري من النوع الثاني باتباع نظام غذائي وممارسة التمرينات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن استخدام فورسيجا بمفرده أو مع أدوية أخرى لعلاج مرض السكري.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من المهم أن تستمر في اتباع الإرشادات التي قدمها لك الطبيب أو الصيدلي أو الممرض حول النظام الغذائي وممارسة التمرينات .</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند البالغين (18 سنة وما فوق) عندما لا يضخ القلب الدم كما ينبغي.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض الكلى المزمن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; عند المرضى الذين يعانون من قصور في وظائف الكلي .</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ما المقصود بمرض السكري من النوع الثاني وكيف يساعد فورسيجا في علاجه ؟</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند الإصابة بمرض السكري من النوع الثاني لا ينتج الجسم ما يكفي من الإنسولين، أو لا يستطيع استخدام الأنسولين الذي ينتجه بطريقة صحيحة. ويؤدي ذلك إلى ارتفاع مستوى السكر في الدم،&nbsp; وهو ما قد يؤدي إلى مشكلات خطيرة مثل أمراض القلب أو الكلى، أو العمى، أو ضعف الدورة الدموية في الذراعين والساقين.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ويحقق فورسيجا أثره بالتخلص من السكر الزائد من الجسم .كما يفيد أيضًا في الوقاية من الإصابة بأمراض القلب .</p><p>&nbsp;</p><p dir="RTL">ما المقصود بقصور القلب وكيف يساعد فورسيجا في علاجه ؟</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحدث هذا النوع من قصور القلب عندما يكون القلب لا يضخ ما يكفي من الدم إلى الرئتين وباقي الجسم، وهذا يمكن أن يؤدي إلى مشكلات طبية خطيرة والحاجة إلى تلقي الرعاية في المستشفى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ومن الأعراض الأكثر شيوعاً لقصور القلب: الشعور بصعوبة في التنفس، والشعور بالتعب أو التعب الشديد طوال الوقت، وتورم الكاحل .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ويساعد فورسيجا على الوقاية من تفاقم سوء القلب ويحسّن الأعراض، ويمكن أن يقلل من الحاجة إلى الذهاب إلى المستشفى وقد يكون سبباً في إطالة عمر بعض المرضى .</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ما المقصود بمرض الكلى المزمن وكيف يساعد فورسيجا في علاجه ؟</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عندما تعاني من مرض الكلى المزمن، فقد تفقد الكليتان وظيفتهما تدريجيًا .وهذا يعني أنهما لن تكونا قادرتين على تنظيف الدم وتنقيته بالطريقة المعتادة. يمكن أن يؤدي فقدان وظائف الكلى إلى مشكلات طبية خطيرة والحاجة إلى دخول المستشفى لتلقي الرعاية اللازمة.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يساعد فورسيجا على حماية الكليتان من فقدان وظائفهما. يمكن أن يساعد فورسيجا بعض المرضى على العيش لفترة أطول .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول فورسيجا</strong>:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية تجاه داباجليفلوزين أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات </strong></p><p dir="RTL">اتصل بطبيب أو توجه إلى أقرب مستشفى فورًا:&nbsp;</p><p dir="RTL">الحُمُاض الكيتوني:&nbsp;</p><p>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت&nbsp; مصاباً بالسكري&nbsp; وعانيت من شعور بالغثيان أو الرغبة في التقيؤ، أو ألم في المعدة، أو عطش شديد، أو التنفس بسرعة وعمق، أو تشوش الذهن، أو حالة غير معتادة من النعاس أو الإعياء، أو نفس له رائحة سكرية، أو مذاق حلو أو معدني في فمك، أو تغير رائحة بولك أو عرقك أ و تغير سريع في الوزن.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تكون هذه الأعراض علامة على &quot;الحُماض الكيتوني السكري&quot;؛ وهي مشكلة خطيرة&nbsp; ولكنها نادرة، وقد تشكل خطراً على الحياة أحياناً، يمكن أن تحدث لك مع السكري بسبب زيادة مستويات &quot;أجسام الكيتون&quot; في بولك أو دمك ،ويمكن الكشف عنها بإجراء تحليلات.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وقد يزيد خطر الإصابة بالحُماض&nbsp; الكيتوني السكري عند الصيام لوقت طويل، أو الإفراط في تعاطي الكحول، أو الجفاف، أو تقليل جرعة الأنسولين فجأة، أو زيادة الحاجة للأنسولين بسبب جراحة كبرى أو مرض خطير.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند علاجك بدواء فورسيجا، فإن الحماض الكيتوني السكري قد يصيبك ولو كان مستوى السكر في دمك طبيعيًا .</p><p>&nbsp;</p><p dir="RTL">إذا كنت تشك في إصابتك بالحماض الكيتوني السكري، فاتصل بطبيب أو أقرب مستشفى إليك فورًا ولا تتناول هذا الدواء . استشر الطبيب أو الصيدلي أو الممرض قبل تناول فورسيجا:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من &quot;مرض السكري من النوع الأول&nbsp; &quot;-&nbsp; وهو نوع يبدأ عادة في الصغر، ولا يفرز الجسم فيه أي إنسولين&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بمرض السكري وتعاني من مشكلة في الكلى - فقد يصف لك طبيبك دواءً إضافياً أو مختلفاً للسيطرة على مستوى السكر في الدم .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلة في الكبد، فقد يبدأ طبيبك معك بتناول جرعة أقل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية لخفض مستوى ضغط الدم (مواد خافضة لضغط الدم) ولديك تاريخ مرضي من ضغط الدم المنخفض (انخفاض ضغط الدم.) ترد المزيد من المعلومات أدناه في الأدوية الأخرى وفورسيجا.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ارتفاع شديد في مستويات السكر في الدم على نحو قد يجعلك عرضة للإصابة بالجفاف (فقدان كمية كبيرة من سوائل الجسم) . ويمكن الاطلاع على العلامات المحتملة للجفاف في القسم&nbsp; 4، &quot;الآثار الجانبية المحتملة.&quot; أخبر طبيبك قبل البدء بتناول فورسيجا، إذا كنت تعاني من أي من هذه العلامات .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالغثيان أو أصبت بالغثيان أو التقيؤ أو الحمى&nbsp;&nbsp; أو إذا تعذر عليك الأكل أو الشرب. قد تؤدي هذه المشكلات إلى الإصابة بالجفاف . وقد يطلب منك الطبيب التوقف عن تناول فورسيجا حتى تتماثل للشفاء للوقاية من الإصابة بالجفاف.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت كثيراً ما تعاني من التهابات المسالك البولية .</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;إذا كان أي مما يلي ينطبق عليك (أو إذا لم تكن متأكدًاً)، فاستشر طبيبك أو الصيدلي أو الممرض قبل تناول فورسيجا .</p><p>&nbsp;</p><p dir="RTL"><strong>مرض السكري والعناية بالقدمين </strong></p><p dir="RTL">إذا كنت مصاباً بالسكري، فمن الضروري أن تفحص قدميك بانتظام وتلتزم بأي نصيحة أخرى بشأن العناية بالقدمين يقدمها اختصاصي الرعاية الصحية المتابع لك.</p><p>&nbsp;</p><p dir="RTL">جلوكوز البو ل بسبب طريقة عمل فورسيجا، فإن أي تحليل للكشف عن السكر في البول ستكون نتيجته إيجابية في أثناء تناول هذا الدواء .</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقو ن </strong></p><p dir="RTL">لا ُيُنُصح بتناول فورسيجا للأطفال والمراهقين الذين يقل عمرهم عن 18 عاًمًا، نظرًا لأنه لم تتم دراسة أثر الدواء على هؤلاء المرضى .</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى&nbsp; وفورسيجا</strong></p><p dir="RTL">&nbsp;أخبر الطبيب أو الصيدلي أو الممرضة إذا كنت تتناول أية أدوية أخرى، أو تناولتها مؤخرًا، أو قد تتناولها في المستقبل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك على وجه الخصوص:&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة تناول دواء يُستخدم للتخلص من الماء من الجسم (مدر للبول.)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية أخرى لخفض مستوى السكر في الدم مثل الأنسولين أو دواء من عائلة &quot;سلفونيل يوريا.&quot; قد يرغب طبيبك في خفض جرعة هذه الأدوية الأخرى لوقايتك من التعرض لانخفاض السكر في الدم (نقص السكر في الدم.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول الليثيوم لأن فورسيجا يمكن أن تخفض كمية الليثيوم في دمك.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">إذا كنتِ حاملاحاملاً أو ترضعين طبيعيًا، أو تعتقدين أنكِ ربما تكونين حاملا ً أو تخططين لإنجاب طفل، فاطلبي نصيحة طبيبك أو الصيدلي قبل تناول هذا الدواء. يجب التوقف عن تناول هذا الدواء إذا أصبحتِ حاملاً، لأنه لا يُنصح بتناوله في أثناء آخر ستة أشهر من الحمل. استشيري طبيبك عن أفضل طريقة للتحكم في مستوى السكر في الدم أثناء الحمل .</p><p>&nbsp;</p><p dir="RTL">تحدثي مع طبيبك إذا كنت ترغبين في الإرضاع طبيعيًا أو إذا كنت ترضعين طبيعيًا قبل تناول هذا الدواء. لا تتناولين فورسيجا إذا كنتِ ترضعين طبيعيًا. لأنه من غير المعروف إذا كان هذا الدواء يُفرز في حليب الأم أم لا .</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">ليس لعقار فورسيجا أي تأثير ُيُذكر على القدرة على القيادة واستخدام الآلات. قد يؤدي تناول هذا الدواء مع أدوية أخرى تُسمى أدوية السلفونيل يوريا أو مع الأنسولين إلى انخفاض شديد في مستوى السكر في الدم (نقص السكر في الدم)، مما قد يؤدي إلى أعراض مثل الرجفة والتعرق وتغيرات في الرؤية، مما قد يؤثر على القدرة على القيادة واستخدام الآلات. لا تقود السيارة أو تستخدم أي أدوات أو آلات إذا كنت تشعر بدوخة عند تناول فورسيجا .</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي فورسيجا على اللاكتو ز </strong></p><p dir="RTL">يحتوي فورسيجا على اللاكتوز (سكر الحليب.) فإذا أخبرك الطبيب أنك لا تحتمل بعض أنواع السكر، فاستشر طبيبك قبل تناول هذا الدواء .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عليك دومًا بتناول هذا الدواء وفقًا لتوجيهات الطبيب تمامًا. ارجع إلى طبيبك أو الصيدلي أو الممرض إذا لم تكن متأكدًا .</p><p dir="RTL">&nbsp;<strong>الجرعة </strong></p><p>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة الموصى بها قرصًا واحدًا 10 ملغ يوميًا .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يبدأ طبيبك بجرعة 5 ملغ إذا كنت تعاني من مشكلة في الكبد .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيصف طبيبك التركيز المناسب لك.</p><p>&nbsp;</p><p dir="RTL"><strong>تناول هذا الدواء </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع القرص كاملاكاملاً مع نصف كوب من الماء .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك تناول القرص مع الطعام أو بدونه .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك تناول القرص في أي وقت من اليوم. ومع ذلك، حاول أن تتناوله في الوقت نفسه من كل يوم، سيساعدك ذلك على تذكر تناوله .</p><p>&nbsp;</p><p dir="RTL">قد يصف لك طبيبك تناول فورسيجا مع دواء آخر (أو أدوية أخرى) . تذكر تناول هذا الدواء الآخر (هذه الأدوية الأخرى) كما وصف طبيبك. فسوف يساعد ذلك على الحصول على أفضل النتائج لصحتك .</p><p>&nbsp;</p><p dir="RTL">يفيد الالتزام بنظام غذائي وممارسة التمارين الرياضية جسمك في استخدام السكر الموجود في الدم على نحو أفضل. ومن المهم أن تستمر في اتباع أي برنامج غذائي وبرنامج تمارين رياضية يوصي به طبيبك أثناء تناول فورسيجا إذا كنت مصاباً بالسكري.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">إذا تناولت جرعة من فورسيجا أكثر مما ينبغ ي في حالة تناول أقراص فورسيجا أكثر مما ينبغي، فاستشر طبيبًا أو اذهب إلى مستشفى فورًا ، وخذ علبة الدواء معك .</p><p>&nbsp;</p><p dir="RTL">إذا نسيت تناول فورسيجا يعتمد ما ينبغي عليك فعله في حالة نسيان تناول قرص على الوقت المتبقي حتى موعد تناول الجرعة التالية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان الوقت المتبقي حتى تناول الجرعة التالية 12 ساعة أو أكثر، فتناول جرعة فورسيجا بمجرد تذكرك. ثم تناول الجرعة التالية في الوقت المعتاد .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان الوقت المتبقي حتى تناول الجرعة التالية أقل من 12 ساعة، فتجاوز الجرعة الفائتة. ثم تناول الجرعة التالية في الوقت المعتاد .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مضاعفة من فورسيجا لتعويض جرعة نسيتها.</p><p>&nbsp;</p><p dir="RTL">إذا توقفت عن تناول فورسيج ا لا تتوقف عن تناول فورسيجا بدون استشارة طبيبك أولاأولاً. إذا كنت مصاباً بالسكري فقد يزيد السكر في الدم لو توقفت عن تناول هذا الدواء .</p><p dir="RTL">&nbsp;استشر طبيبك أو الصيدلي أو الممرضة إذا كانت لديك أي أسئلة أخرى حول استعمال هذا الدواء .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;قد يسبب هذا العقار، شأنه شأن جميع العقاقير، آثاراً جانبية، على الرغم من أنها لا تصيب الجميع .</p><p>&nbsp;</p><p dir="RTL">اتصل بطبيب أو بأقرب مستشفى فورًاً، إذا عانيت من أي من الآثار الجانبية التالية:&nbsp;</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحماض الكيتوني السكري - وهو حالة نادرة بين المرضى المصابين بالنوع الثاني من السكري (قد تصيب ما يصل إلى شخص واحد من بين كل ألف شخص)&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">وفيما يلي علامات الحُماض الكيتوني السكري (انظر أيضًا القس م 2 تحذيرات واحتياطات:) - زيادة مستويات &quot;الأجسام الكيتونية&quot; في البول أو الدم&nbsp;</p><p dir="RTL">-&nbsp; الشعور برغبة في القيئ أو التقيؤ</p><p dir="RTL">-&nbsp; ألم في المعدة&nbsp;</p><p dir="RTL">-&nbsp; العطش الشديد&nbsp;</p><p dir="RTL">-&nbsp; التنفس بسرعة وعمق&nbsp;</p><p dir="RTL">-&nbsp; الارتباك</p><p dir="RTL">-&nbsp; حالة غير معتادة من النعاس أو التعب&nbsp;</p><p dir="RTL">-&nbsp; وجود رائحة سكرية في نفسك، أو مذاق حلو أو معدني في فمك، أو تغير رائحة بولك أو عرقك .</p><p dir="RTL">-&nbsp; نقصان الوزن سريعًا&nbsp; قد يحدث هذا بغض النظر عن مستوى الجلوكوز في الدم. قد يقرر طبيبك إيقاف علاجك بعقار فورسيجا مؤقًتًا أو نهائًيًا .</p><p dir="RTL">&nbsp;توقف عن تناول فورسيجا واستشر طبيبًا في أقرب وقت ممكن إذا لاحظت وجود أيٍّ من الآثار الج انبية الخطيرة التالية:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المسالك البولية، وهو عرض شائع (قد يصيب حتى شخص واحد من بين كل 10 أشخاص) .</p><p dir="RTL">ومن علامات الالتهاب الشديد للمسالك البولية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; حمى و/أو قشعريرة&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; شعور بالحرقان عند التبول&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; ألم في الظهر أو الجنب .</p><p dir="RTL">إذا لاحظت وجود دم في البول، وإن كان ذلك غير شائع، فاخبر طبيبك على الفور .</p><p>&nbsp;</p><p dir="RTL">اتصل بطبيبك في أقرب وقت ممكن إذا لاحظت وجود أيّ من الآثار الجانبية التالية:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات السكر في الدم (نقص سكر الدم)، وهي مشكلة شائعة للغاية (قد تصيب أكثر من شخص واحد من بين كل 10 أشخاص) بين مرضى السكري الذين يتناولون هذا الدواء مع أحد أدوية سلفونيل يوريا أو الأنسولين&nbsp; وعلامات انخفاض السكر في الدم هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الرجفة والعرق الشديد والشعور بقلق شديد وسرعة ضربات القلب&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالجوع والصداع وتغيرات في الرؤية&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; تغير في المزاج أو الشعور بالارتباك سيطلعك طبيبك على كيفية علاج المستويات المنخفضة من السكر في الدم وما الذي ينبغي عليك فعله في حالة التعرض لأيّ من العلامات المذكورة أعلاه.</p><p dir="RTL">&nbsp;الآثار الجانبية الأخرى عند تناول فورسيجا:&nbsp;</p><p dir="RTL">شائعة (قد تؤثر على ما يصل إلى شخص واحد من بين كل 10 أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأعضاء التناسلية (القلاع) للقضيب أو المهبل (قد تتضمن العلامات تهيجًا، أو حكة، أو إفرازات غير اعتيادية، أو رائحةرائحةً غريبة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الظهر&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إخراج كمية أكبر من المعتاد عند التبول أو الحاجة إلى التبول أكثر من المعتاد&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في كمية الكولسترول أو الدهون في الدم (تظهر في الاختبارات)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في عدد خلايا الدم الحمراء في دمك (تظهر في نتائج التحاليل)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص في تصفية الكرياتينين عن طريق الكلى (يظهر في نتائج التحاليل) في بداية العلاج&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي&nbsp;</p><p>&nbsp;</p><p dir="RTL">غير شائعة (قد تؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الكثير من سوائل الجسم (أي الجفاف، ومن علاماته جفاف الفم أو لزوجته الشديدة، أو انخفاض معدل التبول أو عدم التبول على الإطلاق، أو سرعة ضربات القلب)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العطش&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاستيقاظ ليلاليلاً للتبول&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الوزن&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في الكرياتينين (تظهر في الاختبارات المعملية) في بداية العلاج .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في اليوريا (تظهر في اختبارات الدم المعملية)</p><p>&nbsp;</p><p dir="RTL">إذا شعرت بأي آثار جانبية، فتحدّث إلى طبيبك أو الصيدلي أو الممرضة. ويشمل ذلك أي آثار جانبية محتملة غير مذكورة في هذه النشرة .</p><p dir="RTL">&nbsp;</p><p dir="RTL">بلاغ عن أي أثر (آثار) جانبية او اية مشكلات تتعلق بالجودة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المملكه العربيه السعوديه</p><p dir="RTL">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ والسلامة الدوائية:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرقم المجاني : 19999</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دول مجلس التعاون الخليجي الاخرى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يرجى الاتصال بالجهة المختصة ذات الصله</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ هذا الدواء بعيدًا عن متناول الأطفال ورؤيتهم .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ ا نتهاء صلاحيته المدون على الشريط أو العلبة الخارجية بعد كلمة&quot; EXP&quot;.&nbsp; يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المدوّن .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ في درجة حرارة أقل من 30 درجة مئوية .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ترم أية أدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات في حماية البيئة .</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li><p dir="RTL">ما يحتوي عليه فورسيجا</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي داباجليفلوزين.</p><p dir="RTL">يحتوي كل قرص فورسيجا 5 ملغ مغلف (القرص) على مونوهيدرات بروبانديول داباجليفلوزين بما يعادل 5 ملغ داباجليفلوزين .</p><p dir="RTL">يحتوي كل قرص فورسيجا 10 ملغ مغلف (القرص) على مونوهيدرات بروبانديول داباجليفلوزين بما يعادل 10 ملغ داباجليفلوزين .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:&nbsp;</p><p dir="RTL">&minus; &nbsp;&nbsp; مكونات القرص: سيلولوز بلوري مكروي( E460i)، اللاكتوز اللامائي (انظر القسم 2 &quot;يحتوي فورسيجا على اللاكتوز&quot;)، الكروسبوفيدون( E1201)، ثاني أكسيد السيليكون( E551)، ستيارات الماغنسيوم( E470b).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &minus; غلاف القرص الرقيق: كحول البولي فينيل( E1203)، ثاني أكسيد التيتانيوم( E171)، ماكروجول 3350، تلك</p><p dir="RTL">(E553b)، أكسيد الحديد الأصفر( E172).</p></li></ul><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <ul><li><p dir="RTL">شكل فورسيجا ومحتويات العبوة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص فورسيجا 5 ملغ المغلفة هي أقراص صفراء اللون مستديرة قطرها 7,0 سم . مطبوع عليها الرقم&quot; 5&quot; على جانب و&quot;1427&quot; على الجانب الآخر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص فورسيجا 10 ملغ المغلفة هي أقراص صفراء اللون على شكل ماسة قطرها 8,0 &times; 1,1 سم تقريبًا. مطبوع عليها الرقم&quot; 10&quot; على جانب و&quot;1428&quot; على الجانب الآخر .</p><p>&nbsp;</p><p dir="RTL">تتوفر أقراص فورسيجا 5 ملغ و10 ملغ في أشرطة من الألومنيوم في حجم عبوة 28 قرصًا مغلفًا رقيقة في أشرطة مرتبة حسب التقويم وغير مثقبة .</p></li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">حامل ترخيص التسويق والشركة المصنعة حامل ترخيص التسويق:&nbsp;</p><p>AstraZeneca UK Limited,</p><p>600 Capability Green,</p><p>Luton,</p><p>LU1 3LU, UK</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">الشركة المصنعة للمنتج الدوائي&nbsp;</p><p dir="RTL">&nbsp;AstraZeneca UK Limited<br />Silk Road Business Park</p><p dir="RTL">Macclesfield</p><p dir="RTL">SK10 2NA</p><p dir="RTL">United Kingdom</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يناير 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Forxiga 5 mg film-coated tablets
Forxiga 10 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 5 mg tablet contains dapagliflozin propanediol monohydrate equivalent to 5 mg dapagliflozin.
Each 10 mg tablet contains dapagliflozin propanediol monohydrate equivalent to 10 mg dapagliflozin.

Excipient with known effect:
Each 5 mg tablet contains 25 mg of lactose anhydrous.
Each 10 mg tablet contains 50 mg of lactose anhydrous.

For the full list of excipients, see List of excipients.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablet (tablet).

5 mg tablet: Yellow, biconvex, 0.7 cm diameter round, film coated tablets with “5” engraved on one side and “1427” engraved on the other side.
10 mg tablet: Yellow, biconvex, approximately 1.1 x 0.8 cm diagonally diamond shaped, film coated tablets with “10” engraved on one side and “1428” engraved on the other side.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Type 2 diabetes mellitus</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Forxiga is indicated in adults for the treatment of insufficiently controlled type&nbsp;2 diabetes mellitus as an adjunct to diet and exercise</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as monotherapy when metformin is considered inappropriate due to intolerance.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in addition to other medicinal products for the treatment of type&nbsp;2 diabetes.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections&nbsp;4.4, 4.5 and 5.1.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Heart failure</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Forxiga is indicated in adults for the treatment of symptomatic chronic heart failure.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Chronic kidney disease</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Forxiga is indicated in adults for the treatment of chronic kidney disease.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Posology</u></p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Type 2 diabetes mellitus</u></em></p><p dir="ltr">The recommended dose is 10&nbsp;mg dapagliflozin once daily.</p><p dir="ltr">&nbsp;</p><p dir="ltr">When dapagliflozin is used in combination with insulin or an insulin secretagogue, such as a sulphonylurea, a lower dose of insulin or insulin secretagogue may be considered to reduce the risk of hypoglycaemia (see sections&nbsp;4.5 and 4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Heart failure</u></em></p><p dir="ltr">The recommended dose is 10&nbsp;mg dapagliflozin once daily.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Chronic kidney disease</u></em></p><p dir="ltr">The recommended dose is 10&nbsp;mg dapagliflozin once daily.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Special populations</u></em></p><p dir="ltr"><em>Renal impairment</em></p><p dir="ltr">No dose adjustment is required based on renal function.</p><p dir="ltr">&nbsp;</p><p dir="ltr">It is not recommended to initiate treatment with dapagliflozin in patients with an estimated glomerular filtration rate (eGFR)&nbsp;&lt;&nbsp;15&nbsp;mL/min/1.73m<sup>2</sup>.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In patients with type&nbsp;2 diabetes mellitus, the glucose lowering efficacy of dapagliflozin is reduced when eGFR is &lt;&nbsp;45&nbsp;mL/min/1.73m<sup>2</sup>, and is likely absent in patients with severe renal impairment. Therefore, if eGFR falls below 45&nbsp;mL/min/1.73m<sup>2</sup>, additional glucose lowering treatment should be considered in patients with type&nbsp;2 diabetes mellitus (see sections&nbsp;4.4, 4.8, 5.1 and 5.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Hepatic impairment</em></p><p dir="ltr">No dose adjustment is necessary for patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, a starting dose of 5&nbsp;mg is recommended. If well tolerated, the dose may be increased to 10&nbsp;mg (see sections&nbsp;4.4 and 5.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Elderly (&ge;&nbsp;65&nbsp;years)</em></p><p dir="ltr">No dose adjustment is recommended based on age.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Paediatric population</em></p><p dir="ltr">The safety and efficacy of dapagliflozin in children aged 0 to &lt; 18 years have not yet been</p><p dir="ltr">established. No data are available.</p><p dir="ltr"><u>Method of administration</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Forxiga can be taken orally once daily at any time of day with or without food. Tablets are to be swallowed whole.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Renal impairment</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">There is limited experience with initiating treatment with dapagliflozin in patients with eGFR&nbsp;&lt;&nbsp;25&nbsp;mL/min/1.73m<sup>2</sup>, and no experience with initiating treatment in patients with eGFR&nbsp;&lt;&nbsp;15&nbsp;mL/min/1.73m<sup>2</sup>. Therefore, it is not recommended to initiate treatment with dapagliflozin in patients with eGFR&nbsp;&lt;&nbsp;15&nbsp;mL/min/1.73m<sup>2</sup> (see section 4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The glucose lowering efficacy of dapagliflozin is dependent on renal function, and is reduced in patients with eGFR&nbsp;&lt;&nbsp;45&nbsp;mL/min/1.73m<sup>2</sup> and is likely absent in patients with severe renal impairment (see sections&nbsp;4.2, 5.1 and 5.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In patients with moderate renal impairment (eGFR&nbsp;&lt;&nbsp;60&nbsp;mL/min/1.73m<sup>2</sup>), a higher proportion of patients treated with dapagliflozin had adverse reactions of increase in parathyroid hormone (PTH) and hypotension, compared with placebo.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Hepatic impairment</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">There is limited experience in clinical studies in patients with hepatic impairment. Dapagliflozin exposure is increased in patients with severe hepatic impairment (see sections&nbsp;4.2 and 5.2).</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Use in patients at risk for volume depletion and/or hypotension</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Due to its mechanism of action, dapagliflozin increases diuresis which may lead to the modest decrease in blood pressure observed in clinical studies (see section&nbsp;5.1). It may be more pronounced in patients with very high blood glucose concentrations.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Caution should be exercised in patients for whom a dapagliflozin‑induced drop in blood pressure could pose a risk, such as patients on anti‑hypertensive therapy with a history of hypotension or elderly patients.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In case of intercurrent conditions that may lead to volume depletion (e.g. gastrointestinal illness), careful monitoring of volume status (e.g. physical examination, blood pressure measurements, laboratory tests including haematocrit and electrolytes) is recommended. Temporary interruption of treatment with dapagliflozin is recommended for patients who develop volume depletion until the depletion is corrected (see section&nbsp;4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Diabetic ketoacidosis</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Rare cases of diabetic ketoacidosis (DKA), including life-threatening and fatal cases, have been reported in patients treated with sodium-glucose co-transporter&nbsp;2 (SGLT2) inhibitors, including dapagliflozin. In a number of cases, the presentation of the condition was atypical with only moderately increased blood glucose values, below 14&nbsp;mmol/L (250&nbsp;mg/dL).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The risk of diabetic ketoacidosis must be considered in the event of non-specific symptoms such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness. Patients should be assessed for ketoacidosis immediately if these symptoms occur, regardless of blood glucose level.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In patients where DKA is suspected or diagnosed, dapagliflozin treatment should be stopped immediately.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Treatment should be interrupted in patients who are hospitalised for major surgical procedures or acute serious medical illnesses. Monitoring of ketones is recommended in these patients. Measurement of blood ketone levels is preferred to urine. Treatment with dapagliflozin may be restarted when the ketone values are normal and the patient&rsquo;s condition has stabilised.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Before initiating dapagliflozin, factors in the patient history that may predispose to ketoacidosis should be considered.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients who may be at higher risk of DKA include patients with a low beta‑cell function reserve (e.g. type&nbsp;2 diabetes patients with low C‑peptide or latent autoimmune diabetes in adults (LADA) or patients with a history of pancreatitis), patients with conditions that lead to restricted food intake or severe dehydration, patients for whom insulin doses are reduced and patients with increased insulin requirements due to acute medical illness, surgery or alcohol abuse. SGLT2 inhibitors should be used with caution in these patients.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Restarting SGLT2 inhibitor treatment in patients experiencing a DKA while on SGLT2 inhibitor treatment is not recommended, unless another clear precipitating factor is identified and resolved.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In type&nbsp;1 diabetes mellitus studies with dapagliflozin, DKA was reported with common frequency. Dapagliflozin should not be used for treatment of patients with type&nbsp;1 diabetes.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Necrotising fasciitis of the perineum (Fournier&rsquo;s gangrene)</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Postmarketing cases of necrotising fasciitis of the perineum (also known as Fournier&rsquo;s gangrene) have been reported in female and male patients taking SGLT2 inhibitors (see section&nbsp;4.8). This is a rare but serious and potentially life‑threatening event that requires urgent surgical intervention and antibiotic treatment.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients should be advised to seek medical attention if they experience a combination of symptoms of pain, tenderness, erythema, or swelling in the genital or perineal area, with fever or malaise. Be aware that either uro‑genital infection or perineal abscess may precede necrotising fasciitis. If Fournier&rsquo;s gangrene is suspected, Forxiga should be discontinued and prompt treatment (including antibiotics and surgical debridement) should be instituted.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Urinary tract infections</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Urinary glucose excretion may be associated with an increased risk of urinary tract infection; therefore, temporary interruption of dapagliflozin should be considered when treating pyelonephritis or urosepsis.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Elderly (&ge;&nbsp;65&nbsp;years)</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Elderly patients may be at a greater risk for volume depletion and are more likely to be treated with diuretics.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Elderly patients are more likely to have impaired renal function, and/or to be treated with anti‑hypertensive medicinal products that may cause changes in renal function such as angiotensin‑converting enzyme inhibitors (ACE‑I) and angiotensin&nbsp;II type&nbsp;1 receptor blockers (ARB). The same recommendations for renal function apply to elderly patients as to all patients (see sections&nbsp;4.2, 4.4, 4.8 and 5.1).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Cardiac failure</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Experience with dapagliflozin in NYHA&nbsp;class&nbsp;IV is limited.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Chronic kidney disease</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">There is no experience with dapagliflozin for the treatment of chronic kidney disease in patients without diabetes who do not have albuminuria.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Dapagliflozin has not been studied for the treatment of chronic kidney disease in patients with polycystic kidney disease, glomerulonephritis with flares (lupus nephritis or ANCA-associated vasculitis), ongoing or recent requirements of cytotoxic, immunosuppressive or other immunomodulating renal therapy, or in patients who received an organ transplant.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Lower limb amputations</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">An increase in cases of lower limb amputation (primarily of the toe) has been observed in long-term, clinical studies in type&nbsp;2 diabetes mellitus with SGLT2 inhibitors. It is unknown whether this constitutes a class effect. It is important to counsel patients with diabetes on routine preventative foot care.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Urine laboratory assessments</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Due to its mechanism of action, patients taking Forxiga will test positive for glucose in their urine.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Lactose</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Pharmacodynamic interactions</u></p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Diuretics</u></em></p><p dir="ltr">Dapagliflozin may add to the diuretic effect of thiazide and loop diuretics and may increase the risk of dehydration and hypotension (see section&nbsp;4.4).</p><p dir="ltr"><em><u>&nbsp;</u></em></p><p dir="ltr"><em><u>Insulin and insulin secretagogues</u></em></p><p dir="ltr">Insulin and insulin secretagogues, such as sulphonylureas, cause hypoglycaemia. Therefore, a lower dose of insulin or an insulin secretagogue may be required to reduce the risk of hypoglycaemia when used in combination with dapagliflozin in patients with type&nbsp;2 diabetes mellitus (see sections&nbsp;4.2 and 4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Pharmacokinetic interactions</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The metabolism of dapagliflozin is primarily via glucuronide conjugation mediated by UDP&nbsp;glucuronosyltransferase&nbsp;1A9 (UGT1A9).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In <em>in vitro</em> studies, dapagliflozin neither inhibited cytochrome&nbsp;P450&nbsp;(CYP)&nbsp;1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, nor induced CYP1A2, CYP2B6 or CYP3A4. Therefore, dapagliflozin is not expected to alter the metabolic clearance of coadministered medicinal products that are metabolised by these enzymes.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Effect of other medicinal products on dapagliflozin</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Interaction studies conducted in healthy subjects, using mainly a single‑dose design, suggest that the pharmacokinetics of dapagliflozin are not altered by metformin, pioglitazone, sitagliptin, glimepiride, voglibose, hydrochlorothiazide, bumetanide, valsartan, or simvastatin.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Following coadministration of dapagliflozin with rifampicin (an inducer of various active transporters and drug‑metabolising enzymes) a 22% decrease in dapagliflozin systemic exposure&nbsp;(AUC) was observed, but with no clinically meaningful effect on 24‑hour urinary glucose excretion. No dose adjustment is recommended. A clinically relevant effect with other inducers (e.g. carbamazepine, phenytoin, phenobarbital) is not expected.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Following coadministration of dapagliflozin with mefenamic&nbsp;acid (an inhibitor of UGT1A9), a 55% increase in dapagliflozin systemic exposure was seen, but with no clinically meaningful effect on 24‑hour urinary glucose excretion. No dose adjustment is recommended.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Effect of dapagliflozin on other medicinal products</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Dapagliflozin may increase renal lithium excretion and the blood lithium levels may be decreased. Serum concentration of lithium should be monitored more frequently after dapagliflozin initiation and dose changes. Please refer the patient to the lithium prescribing doctor in order to monitor serum concentration of lithium.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In interaction studies conducted in healthy subjects, using mainly a single‑dose design, dapagliflozin did not alter the pharmacokinetics of metformin, pioglitazone, sitagliptin, glimepiride, hydrochlorothiazide, bumetanide, valsartan, digoxin (a P‑gp substrate) or warfarin (S‑warfarin, a CYP2C9 substrate), or the anticoagulatory effects of warfarin as measured by INR. Combination of a single dose of dapagliflozin 20&nbsp;mg and simvastatin (a CYP3A4 substrate) resulted in a 19% increase in AUC of simvastatin and 31% increase in AUC of simvastatin acid. The increase in simvastatin and simvastatin acid exposures are not considered clinically relevant.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Interference with 1,5-anhydroglucitol (1,5-AG) assay</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Monitoring glycaemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycaemic control in patients taking SGLT2 inhibitors. Use of alternative methods to monitor glycaemic control is advised.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Paediatric population</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Pregnancy</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">There are no data from the use of dapagliflozin in pregnant women. Studies in rats have shown toxicity to the developing kidney in the time period corresponding to the second and third trimesters of human pregnancy (see section&nbsp;5.3). Therefore, the use of dapagliflozin is not recommended during the second and third trimesters of pregnancy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">When pregnancy is detected, treatment with dapagliflozin should be discontinued.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Breast‑feeding</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">It is unknown whether dapagliflozin and/or its metabolites are excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of dapagliflozin/metabolites in milk, as well as pharmacologically-mediated effects in nursing offspring (see section&nbsp;5.3). A risk to the newborns/infants cannot be excluded. Dapagliflozin should not be used while breast‑feeding.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Fertility</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The effect of dapagliflozin on fertility in humans has not been studied. In male and female rats, dapagliflozin showed no effects on fertility at any dose tested.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Forxiga has no or negligible influence on the ability to drive and use machines. Patients should be alerted to the risk of hypoglycaemia when dapagliflozin is used in combination with a sulphonylurea or insulin</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Summary of the safety profile</u></p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Type 2 diabetes mellitus</u></em></p><p dir="ltr">In the clinical studies in type&nbsp;2 diabetes, more than 15,000&nbsp;patients have been treated with dapagliflozin.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The primary assessment of safety and tolerability was conducted in a pre‑specified pooled analysis of 13&nbsp;short-term (up to 24&nbsp;weeks) placebo-controlled studies with 2,360&nbsp;subjects treated with dapagliflozin&nbsp;10&nbsp;mg and 2,295 treated with placebo.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the dapagliflozin cardiovascular outcomes study in type&nbsp;2 diabetes mellitus (DECLARE study, see section&nbsp;5.1), 8,574&nbsp;patients received dapagliflozin 10&nbsp;mg and 8,569 received placebo for a median exposure time of 48&nbsp;months. In total, there were 30,623&nbsp;patient-years of exposure to dapagliflozin.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The most frequently reported adverse reactions across the clinical studies were genital infections.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Heart failure</u></em></p><p dir="ltr">In the dapagliflozin cardiovascular outcome study in patients with heart failure with reduced ejection fraction (DAPA-HF study), 2,368&nbsp;patients were treated with dapagliflozin 10&nbsp;mg and 2,368&nbsp;patients with placebo for a median exposure time of 18&nbsp;months. The patient population included patients with type&nbsp;2 diabetes mellitus and without diabetes, and patients with eGFR&nbsp;&ge;&nbsp;30&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>. In the dapagliflozin cardiovascular outcome study in patients with heart failure with left ventricular ejection fraction &gt;&nbsp;40% (DELIVER), 3,126&nbsp;patients were treated with dapagliflozin 10&nbsp;mg and 3,127&nbsp;patients with placebo for a median exposure time of 27&nbsp;months. The patient population included patients with type&nbsp;2 diabetes mellitus and without diabetes, and patients with eGFR&nbsp;&ge;&nbsp;25&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The overall safety profile of dapagliflozin in patients with heart failure was consistent with the known safety profile of dapagliflozin.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Chronic kidney disease</u></em></p><p dir="ltr">In the dapagliflozin renal outcome study in patients with chronic kidney disease (DAPA-CKD), 2,149&nbsp;patients were treated with dapagliflozin 10&nbsp;mg and 2,149&nbsp;patients with placebo for a median exposure time of 27 months. The patient population included patients with type 2 diabetes mellitus and without diabetes, with eGFR&nbsp;&ge;&nbsp;25&nbsp;to &le;&nbsp;75&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>. Treatment was continued if eGFR fell to levels below&nbsp;25&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The overall safety profile of dapagliflozin in patients with chronic kidney disease was consistent with the known safety profile of dapagliflozin.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Tabulated list of adverse reactions</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The following adverse reactions have been identified in the placebo-controlled clinical studies and postmarketing surveillance. None were found to be dose-related. Adverse reactions listed below are classified according to frequency and system organ class (SOC). Frequency categories are defined according to the following convention: very common&nbsp;(&ge;&nbsp;1/10), common&nbsp;(&ge;&nbsp;1/100&nbsp;to&nbsp;&lt;&nbsp;1/10), uncommon&nbsp;(&ge;&nbsp;1/1,000&nbsp;to&nbsp;&lt;&nbsp;1/100), rare (&ge;&nbsp;1/10,000&nbsp;to&nbsp;&lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000), and not known (cannot be estimated from the available data).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table&nbsp;1. Adverse reactions in placebo-controlled clinical studies<sup>a</sup> and postmarketing experience</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common<sup>*</sup></strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Uncommon<sup>**</sup></strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><em>Infections and infestations</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vulvovaginitis, balanitis and related genital infections<sup>*,b,c</sup></p><p>Urinary tract infection<sup>*,b,d</sup></p></td><td style="vertical-align:top"><p>Fungal infection<sup>**</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Necrotising fasciitis of the perineum (Fournier&#39;s gangrene)<sup>b,i</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Metabolism and nutrition disorders</em></p></td><td style="vertical-align:top"><p>Hypoglycaemia (when used with SU or insulin)<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Volume depletion<sup>b,e</sup></p><p>Thirst<sup>**</sup></p></td><td style="vertical-align:top"><p>Diabetic ketoacidosis<br />(when used in type&nbsp;2 diabetes mellitus)<sup>b,i,k</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous system disorders</em></p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td><td style="vertical-align:top"><p>Constipation<sup>**</sup></p><p>Dry mouth<sup>**</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash<sup>j</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angioedema</p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Back pain<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dysuria</p><p>Polyuria<sup>*,f</sup></p></td><td style="vertical-align:top"><p>Nocturia<sup>**</sup></p><p><s>&nbsp;</s></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Reproductive system and breast disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vulvovaginal pruritus<sup>**</sup></p><p>Pruritus genital<sup>**</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Investigations</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haematocrit increased<sup>g</sup></p><p>Creatinine renal clearance decreased during initial treatment<sup>b</sup></p><p>Dyslipidaemia<sup>h</sup></p></td><td style="vertical-align:top"><p>Blood creatinine increased during initial treatment<sup>**,b</sup></p><p>Blood urea increased<sup>**</sup></p><p>Weight decreased<sup>**</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr"><sup>a</sup>The table shows up to 24‑week (short‑term) data regardless of glycaemic rescue.</p><p dir="ltr"><sup>b</sup>See corresponding subsection below for additional information.</p><p dir="ltr"><sup>c</sup>Vulvovaginitis, balanitis and related genital infections includes, e.g. the predefined preferred terms: vulvovaginal mycotic infection, vaginal infection, balanitis, genital infection fungal, vulvovaginal candidiasis, vulvovaginitis, balanitis candida, genital candidiasis, genital infection, genital infection male, penile infection, vulvitis, vaginitis bacterial, vulval abscess.</p><p dir="ltr"><sup>d</sup>Urinary tract infection includes the following preferred terms, listed in order of frequency reported: urinary tract infection, cystitis, Escherichia urinary tract infection, genitourinary tract infection, pyelonephritis, trigonitis, urethritis, kidney infection and prostatitis.</p><p dir="ltr"><sup>e</sup>Volume depletion includes, e.g. the predefined preferred terms: dehydration, hypovolaemia, hypotension.</p><p dir="ltr"><sup>f</sup>Polyuria includes the preferred terms: pollakiuria, polyuria, urine output increased.</p><p dir="ltr"><sup>g</sup>Mean changes from baseline in haematocrit were 2.30% for dapagliflozin&nbsp;10&nbsp;mg versus &ndash;0.33% for placebo. Haematocrit values &gt;55% were reported in 1.3% of the subjects treated with dapagliflozin 10&nbsp;mg versus 0.4% of placebo subjects.</p><p dir="ltr"><sup>h</sup>Mean percent change from baseline for dapagliflozin&nbsp;10&nbsp;mg versus placebo, respectively, was: total cholesterol 2.5% versus 0.0%; HDL cholesterol 6.0% versus 2.7%; LDL cholesterol 2.9% versus ‑1.0%; triglycerides&nbsp;‑2.7% versus ‑0.7%.</p><p dir="ltr"><sup>i</sup>See section 4.4.</p><p dir="ltr"><sup>j</sup>Adverse reaction was identified through postmarketing surveillance. Rash includes the following preferred terms, listed in order of frequency in clinical studies: rash, rash generalised, rash pruritic, rash macular, rash maculo-papular, rash pustular, rash vesicular, and rash erythematous. In active- and placebo-controlled clinical studies (dapagliflozin, N=5936, All control, N=3403), the frequency of rash was similar for dapagliflozin (1.4%) and all control (1.4%), respectively.</p><p dir="ltr"><sup>k</sup>Reported in the cardiovascular outcomes study in patients with type&nbsp;2 diabetes (DECLARE). Frequency is based on annual rate.</p><p dir="ltr"><sup>*</sup>Reported in &ge;&nbsp;2% of subjects and &ge;&nbsp;1% more and at least 3 more subjects treated with dapagliflozin&nbsp;10&nbsp;mg compared to placebo.</p><p dir="ltr"><sup>**</sup>Reported by the investigator as possibly related, probably related or related to study treatment and reported in &ge;&nbsp;0.2% of subjects and &ge;&nbsp;0.1% more and at least 3&nbsp;more subjects treated with dapagliflozin&nbsp;10&nbsp;mg compared to placebo.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Description of selected adverse reactions</u></p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Vulvovaginitis, balanitis and related genital infections</u></em></p><p dir="ltr">In the 13-study safety pool, vulvovaginitis, balanitis and related genital infections were reported in 5.5% and 0.6% of subjects who received dapagliflozin&nbsp;10&nbsp;mg and placebo, respectively. Most infections were mild to moderate, and subjects responded to an initial course of standard treatment and rarely resulted in discontinuation from dapagliflozin treatment. These infections were more frequent in females (8.4% and 1.2% for dapagliflozin and placebo, respectively), and subjects with a prior history were more likely to have a recurrent infection.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the DECLARE study, the numbers of patients with serious adverse events of genital infections were few and balanced: 2&nbsp;patients in each of the dapagliflozin and placebo groups.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the DAPA-HF study, no patient reported serious adverse events of genital infections in the dapagliflozin group and one in the placebo group. There were 7&nbsp;(0.3%)&nbsp;patients with adverse events leading to discontinuations due to genital infections in the dapagliflozin group and none in the placebo group. In the DELIVER study, one&nbsp;(&lt;&nbsp;0.1%)&nbsp;patient in each treatment group reported a serious adverse event of genital infections. There were 3&nbsp;(0.1%)&nbsp;patients with adverse events leading to discontinuations due to genital infection in the dapagliflozin group and none in the placebo group.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the DAPA-CKD study, there were 3&nbsp;(0.1%) patients with serious adverse events of genital infections in the dapagliflozin group and none in the placebo group. There were 3&nbsp;(0.1%) patients with adverse events leading to discontinuation due to genital infections in the dapagliflozin group and none in the placebo group. Serious adverse events of genital infections or adverse events leading to discontinuation due to genital infections were not reported for any patients without diabetes.</p><p>Cases of phimosis/acquired phimosis have been reported concurrent with genital infections and in some cases, circumcision was required.</p><p dir="ltr"><em><u>Necrotising fasciitis of the perineum (Fournier&rsquo;s gangrene)</u></em></p><p dir="ltr">Cases of Fournier&rsquo;s gangrene have been reported postmarketing in patients taking SGLT2 inhibitors, including dapagliflozin (see section&nbsp;4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the DECLARE study with 17,160&nbsp;type&nbsp;2 diabetes mellitus patients and a median exposure time of 48&nbsp;months, a total of 6&nbsp;cases of Fournier&rsquo;s gangrene were reported, one in the dapagliflozin-treated group and 5 in the placebo group.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Hypoglycaemia</u></em></p><p dir="ltr">The frequency of hypoglycaemia depended on the type of background therapy used in the clinical studies in diabetes mellitus.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For studies of dapagliflozin in monotherapy, as add‑on to metformin or as add‑on to sitagliptin (with or without metformin), the frequency of minor episodes of hypoglycaemia was similar (&lt;&nbsp;5%) between treatment groups, including placebo up to 102&nbsp;weeks of treatment. Across all studies, major events of hypoglycaemia were uncommon and comparable between the groups treated with dapagliflozin or placebo. Studies with add‑on sulphonylurea and add‑on insulin therapies had higher rates of hypoglycaemia (see section&nbsp;4.5).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In an add‑on to glimepiride study, at weeks 24 and 48, minor episodes of hypoglycaemia were reported more frequently in the group treated with dapagliflozin&nbsp;10&nbsp;mg plus glimepiride (6.0% and 7.9%, respectively) than in the placebo plus glimepiride group (2.1% and 2.1%, respectively).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In an add‑on to insulin study, episodes of major hypoglycaemia were reported in 0.5% and 1.0% of subjects treated with dapagliflozin&nbsp;10&nbsp;mg plus insulin at weeks 24 and 104, respectively, and in 0.5% of subjects treated with placebo plus insulin groups at weeks 24 and 104. At weeks 24 and 104, minor episodes of hypoglycaemia were reported, respectively, in 40.3% and 53.1% of subjects who received dapagliflozin 10&nbsp;mg plus insulin and in 34.0% and 41.6% of the subjects who received placebo plus insulin.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In an add-on to metformin and a sulphonylurea study, up to 24&nbsp;weeks, no episodes of major hypoglycaemia were reported. Minor episodes of hypoglycaemia were reported in 12.8% of subjects who received dapagliflozin 10&nbsp;mg plus metformin and a sulphonylurea and in 3.7% of subjects who received placebo plus metformin and a sulphonylurea.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the DECLARE study, no increased risk of major hypoglycaemia was observed with dapagliflozin therapy compared with placebo. Major events of hypoglycaemia were reported in 58&nbsp;(0.7%)&nbsp;patients treated with dapagliflozin and 83&nbsp;(1.0%)&nbsp;patients treated with placebo.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the DAPA-HF study, major events of hypoglycaemia were reported in 4&nbsp;(0.2%)&nbsp;patients in both the dapagliflozin and placebo treatment groups. In the DELIVER study, major events of hypoglycaemia were reported in 6&nbsp;(0.2%)&nbsp;patients in the dapagliflozin group and 7&nbsp;(0.2%) in the placebo group. Major events of hypoglycaemia were only observed in patients with type&nbsp;2 diabetes mellitus.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the DAPA-CKD study, major events of hypoglycaemia were reported in 14&nbsp;(0.7%) patients in the dapagliflozin group and 28&nbsp;(1.3%) patients in the placebo group and observed only in patients with type 2 diabetes mellitus.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Volume depletion</u></em></p><p dir="ltr">In the 13-study safety pool, reactions suggestive of volume depletion (including, reports of dehydration, hypovolaemia or hypotension) were reported in 1.1% and 0.7% of subjects who received dapagliflozin<strong>&nbsp;</strong>10&nbsp;mg and placebo, respectively; serious reactions occurred in &lt;&nbsp;0.2% of subjects balanced between dapagliflozin&nbsp;10&nbsp;mg and placebo (see section&nbsp;4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the DECLARE study, the numbers of patients with events suggestive of volume depletion were balanced between treatment groups: 213&nbsp;(2.5%) and 207&nbsp;(2.4%) in the dapagliflozin and placebo groups, respectively. Serious adverse events were reported in 81&nbsp;(0.9%) and 70&nbsp;(0.8%) in the dapagliflozin and placebo group, respectively. Events were generally balanced between treatment groups across subgroups of age, diuretic use, blood pressure and angiotensin converting enzyme inhibitors (ACE‑I)/angiotensin&nbsp;II type&nbsp;1 receptor blockers (ARB) use. In patients with eGFR &lt;&nbsp;60&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> at baseline, there were 19&nbsp;events of serious adverse events suggestive of volume depletion in the dapagliflozin group and 13&nbsp;events in the placebo group.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the DAPA-HF study, the numbers of patients with events suggestive of volume depletion were 170&nbsp;(7.2%) in the dapagliflozin group and 153&nbsp;(6.5%) in the placebo group. There were fewer patients with serious events of symptoms suggestive of volume depletion in the dapagliflozin group (23&nbsp;[1.0%]) compared with the placebo group (38&nbsp;[1.6%]). Results were similar irrespective of presence of diabetes at baseline and baseline eGFR. In the DELIVER study, the numbers of patients with serious events of symptoms suggestive of volume depletion were 35&nbsp;(1.1%) in the dapagliflozin group and 31&nbsp;(1.0%) in the placebo group.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the DAPA-CKD study, the numbers of patients with events suggestive of volume depletion were&nbsp;120&nbsp;(5.6%) in the dapagliflozin group and 84&nbsp;(3.9%) in the placebo group. There were&nbsp;16&nbsp;(0.7%)&nbsp;patients with serious events of symptoms suggestive of volume depletion in the dapagliflozin group and&nbsp;15&nbsp;(0.7%)&nbsp;patients in the placebo group.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Diabetic ketoacidosis in type 2 diabetes mellitus</u></em></p><p dir="ltr">In the DECLARE study, with a median exposure time of 48&nbsp;months, events of DKA were reported in 27&nbsp;patients in the dapagliflozin 10&nbsp;mg group and 12&nbsp;patients in the placebo group. The events occurred evenly distributed over the study period. Of the 27&nbsp;patients with DKA events in the dapagliflozin group, 22 had concomitant insulin treatment at the time of the event. Precipitating factors for DKA were as expected in a type&nbsp;2 diabetes mellitus population (see section&nbsp;4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the DAPA-HF study, events of DKA were reported in 3&nbsp;patients with type&nbsp;2 diabetes mellitus in the dapagliflozin group and none in the placebo group. In the DELIVER study, events of DKA were reported in 2&nbsp;patients with type&nbsp;2 diabetes mellitus in the dapagliflozin group and none in the placebo group.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the DAPA-CKD study, events of DKA were not reported in any&nbsp;patient in the dapagliflozin group and in 2&nbsp;patients with type 2 diabetes mellitus in the placebo group.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Urinary tract infections</u></em></p><p dir="ltr">In the 13-study safety pool, urinary tract infections were more frequently reported for dapagliflozin&nbsp;10&nbsp;mg compared to placebo (4.7% versus 3.5%, respectively; see section&nbsp;4.4). Most infections were mild to moderate, and subjects responded to an initial course of standard treatment and rarely resulted in discontinuation from dapagliflozin treatment. These infections were more frequent in females, and subjects with a prior history were more likely to have a recurrent infection.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the DECLARE study, serious events of urinary tract infections were reported less frequently for dapagliflozin 10&nbsp;mg compared with placebo, 79&nbsp;(0.9%)&nbsp;events versus 109&nbsp;(1.3%)&nbsp;events, respectively.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the DAPA-HF study, the numbers of patients with serious adverse events of urinary tract infections were 14&nbsp;(0.6%) in the dapagliflozin group and 17&nbsp;(0.7%) in the placebo group. There were 5&nbsp;(0.2%) patients with adverse events leading to discontinuations due to urinary tract infections in each of the dapagliflozin and placebo groups. In the DELIVER study the numbers of patients with serious adverse events of urinary tract infections were 41&nbsp;(1.3%) in the dapagliflozin group and 37&nbsp;(1.2%) in the placebo group. There were 13&nbsp;(0.4%)&nbsp;patients with adverse events leading to discontinuations due to urinary tract infections in the dapagliflozin group and 9&nbsp;(0.3%) in the placebo group.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the DAPA-CKD study, the numbers of patients with serious adverse events of urinary tract infections were 29&nbsp;(1.3%) in the dapagliflozin group and 18&nbsp;(0.8%) in the placebo group. There were 8&nbsp;(0.4%) patients with adverse events leading to discontinuations due to urinary tract infections in the dapagliflozin group and 3&nbsp;(0.1%) in the placebo group. &nbsp;The numbers of patients without diabetes</p><p dir="ltr">reporting serious adverse events of urinary tract infections or adverse events leading to discontinuation</p><p dir="ltr">due to urinary tract infections were similar between treatment groups (6 [0.9%] versus 4 [0.6%] for</p><p dir="ltr">serious adverse events, and 1 [0.1%] versus 0 for adverse events leading to discontinuation, in the</p><p dir="ltr">dapagliflozin and placebo groups, respectively).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Increased creatinine</u></em></p><p dir="ltr">Adverse reactions related to increased creatinine were grouped (e.g. decreased renal creatinine clearance, renal impairment, increased blood creatinine and decreased glomerular filtration rate). In the 13-study safety pool, this grouping of reactions was reported in 3.2% and 1.8% of patients who received dapagliflozin 10&nbsp;mg and placebo, respectively. In patients with normal renal function or mild renal impairment (baseline eGFR&nbsp;&ge;&nbsp;60&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>) this grouping of reactions were reported in 1.3% and 0.8% of patients who received dapagliflozin 10&nbsp;mg and placebo, respectively. These reactions were more common in patients with baseline eGFR&nbsp;&ge;&nbsp;30 and &lt;&nbsp;60&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> (18.5% dapagliflozin 10&nbsp;mg versus 9.3% placebo).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Further evaluation of patients who had renal-related adverse events showed that most had serum creatinine changes of &le; 44 micromoles/L&nbsp;(&le;&nbsp;0.5&nbsp;mg/Dl) from baseline. The increases in creatinine were generally transient during continuous treatment or reversible after discontinuation of treatment.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the DECLARE study, including elderly patients and patients with renal impairment (eGFR less than 60&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>), eGFR decreased over time in both treatment groups. At 1&nbsp;year, mean eGFR was slightly lower, and at 4&nbsp;years, mean eGFR was slightly higher in the dapagliflozin group compared with the placebo group.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the DAPA-HF and DELIVER studies, eGFR decreased over time in both the dapagliflozin group and the placebo group. In DAPA-HF, the initial decrease in mean eGFR was ‑4.3&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> in the dapagliflozin group and ‑1.1&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> in the placebo group. At 20&nbsp;months, change from baseline in eGFR was similar between the treatment groups: ‑5.3&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> for dapagliflozin and ‑4.5&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> for placebo. In DELIVER, the decrease in mean eGFR at one&nbsp;month was ‑3.7&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> in the dapagliflozin group and ‑0.4&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> in the placebo group. At 24&nbsp;months, change from baseline in eGFR was similar between treatment groups: ‑4.2&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> in the dapagliflozin group and ‑3.2&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> in the placebo group.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the DAPA-CKD study, eGFR decreased over time in both the dapagliflozin group and the placebo group. The initial (day 14) decrease in mean eGFR was ‑4.0&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> in the dapagliflozin group and ‑0.8&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> in the placebo group. At 28&nbsp;months, change from baseline in eGFR was ‑7.4&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> in the dapagliflozin group and ‑8.6&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> in the placebo group.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">To report any side effect(s):</p><ul dir="ltr"><li><strong><em>Saudi Arabia: </em></strong></li></ul><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>- The National Pharmacovigilance Centre (NPC)</p><p>o&nbsp;&nbsp; SFDA Call Center: 19999</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa &nbsp;&nbsp;</p><p>o&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp; Other GCC States:</p><p dir="ltr">&nbsp;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Dapagliflozin did not show any toxicity in healthy subjects at single oral doses up to 500&nbsp;mg (50&nbsp;times the maximum recommended human dose). These subjects had detectable glucose in the urine for a dose‑related period of time (at least 5&nbsp;days for the 500&nbsp;mg dose), with no reports of dehydration, hypotension or electrolyte imbalance, and with no clinically meaningful effect on QTc interval. The incidence of hypoglycaemia was similar to placebo. In clinical studies where once‑daily doses of up to 100&nbsp;mg (10&nbsp;times the maximum recommended human dose) were administered for 2&nbsp;weeks in healthy subjects and type&nbsp;2 diabetes subjects, the incidence of hypoglycaemia was slightly higher than placebo and was not dose‑related. Rates of adverse events including dehydration or hypotension were similar to placebo, and there were no clinically meaningful dose‑related changes in laboratory parameters, including serum electrolytes and biomarkers of renal function.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient&rsquo;s clinical status. The removal of dapagliflozin by haemodialysis has not been studied.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Drugs used in diabetes, sodium-glucose co-transporter 2 (SGLT2) inhibitors, ATC code: A10BK01</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Mechanism of action</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Dapagliflozin is a highly potent (K<sub>i</sub>:&nbsp;0.55&nbsp;nM), selective and reversible inhibitor of SGLT2.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Inhibition of SGLT2 by dapagliflozin reduces reabsorption of glucose from the glomerular filtrate in the proximal renal tubule with a concomitant reduction in sodium reabsorption leading to urinary excretion of glucose and osmotic diuresis. Dapagliflozin therefore increases the delivery of sodium to the distal tubule which increases tubuloglomerular feedback and reduces intraglomerular pressure. This combined with osmotic diuresis leads to a reduction in volume overload, reduced blood pressure, and lower preload and afterload, which may have beneficial effects on cardiac remodelling and diastolic function, and preserve renal function. The cardiac and renal benefits of dapagliflozin go beyond the blood glucose-lowering effect and are not limited to patients with diabetes as demonstrated in the DAPA-HF, DELIVER and DAPA‑CKD studies. Other effects include an increase in haematocrit and reduction in body weight.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Dapagliflozin improves both fasting and post‑prandial plasma glucose levels by reducing renal glucose reabsorption leading to urinary glucose excretion. This glucose excretion (glucuretic effect) is observed after the first dose, is continuous over the 24‑hour dosing interval and is sustained for the duration of treatment. The amount of glucose removed by the kidney through this mechanism is dependent upon the blood glucose concentration and GFR. Thus, in subjects with normal blood glucose and/or low GFR, dapagliflozin has a low propensity to cause hypoglycaemia, as the amount of filtrated glucose is small and can be reabsorbed by SGLT1 and unblocked SGLT2 transporters. Dapagliflozin does not impair normal endogenous glucose production in response to hypoglycaemia. Dapagliflozin acts independently of insulin secretion and insulin action. Improvement in homeostasis model assessment for beta cell function (HOMA beta‑cell) has been observed in clinical studies with dapagliflozin.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The SGLT2 is selectively expressed in the kidney. Dapagliflozin does not inhibit other glucose transporters important for glucose transport into peripheral tissues and is &gt;&nbsp;1,400&nbsp;times more selective for SGLT2 versus SGLT1, the major transporter in the gut responsible for glucose absorption.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Pharmacodynamic effects</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Increases in the amount of glucose excreted in the urine were observed in healthy subjects and in subjects with type&nbsp;2 diabetes mellitus following the administration of dapagliflozin. Approximately 70&nbsp;g of glucose was excreted in the urine per day (corresponding to 280&nbsp;kcal/day) at a dapagliflozin dose of 10&nbsp;mg/day in subjects with type&nbsp;2 diabetes mellitus for 12&nbsp;weeks. Evidence of sustained glucose excretion was seen in subjects with type&nbsp;2 diabetes mellitus given dapagliflozin&nbsp;10&nbsp;mg/day for up to 2&nbsp;years.</p><p dir="ltr">&nbsp;</p><p dir="ltr">This urinary glucose excretion with dapagliflozin also results in osmotic diuresis and increases in urinary volume in subjects with type&nbsp;2 diabetes mellitus. Urinary volume increases in subjects with type&nbsp;2 diabetes mellitus treated with dapagliflozin 10&nbsp;mg were sustained at 12&nbsp;weeks and amounted to approximately 375&nbsp;mL/day. The increase in urinary volume was associated with a small and transient increase in urinary sodium excretion that was not associated with changes in serum sodium concentrations.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Urinary uric acid excretion was also increased transiently (for 3‑7 days) and accompanied by a sustained reduction in serum uric acid concentration. At 24&nbsp;weeks, reductions in serum uric acid concentrations ranged from ‑48.3&nbsp;to&nbsp;‑18.3&nbsp;micromoles/L (‑0.87&nbsp;to&nbsp;‑0.33&nbsp;mg/dL).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Clinical efficacy and safety</u></p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Type 2 diabetes mellitus</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Improvement of glycaemic control and reduction of cardiovascular and renal morbidity and mortality are integral parts of the treatment of type&nbsp;2 diabetes.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Fourteen double‑blind, randomised, controlled clinical studies were conducted with 7,056&nbsp;adult subjects with type&nbsp;2 diabetes to evaluate the glycaemic efficacy and safety of Forxiga; 4,737&nbsp;subjects in these studies were treated with dapagliflozin. Twelve studies had a treatment period of 24&nbsp;weeks duration, 8&nbsp;with long‑term extensions ranging from 24 to 80&nbsp;weeks (up to a total study duration of 104&nbsp;weeks), one study had a 28‑week treatment period, and one study was 52&nbsp;weeks in duration with long‑term extensions of 52 and 104&nbsp;weeks (total study duration of 208&nbsp;weeks). Mean duration of diabetes ranged from 1.4 to 16.9&nbsp;years. Fifty percent (50%) had mild renal impairment and 11% had moderate renal impairment. Fifty‑one percent (51%) of the subjects were men, 84% were White, 8% were Asian, 4%&nbsp;were Black and 4% were of other racial groups. Eighty‑one&nbsp;percent (81%) of the subjects had a body mass index (BMI)&nbsp;&sup3;&nbsp;27. Furthermore, two 12-week, placebo-controlled studies were conducted in patients with inadequately controlled type 2 diabetes and hypertension.</p><p dir="ltr">&nbsp;</p><p dir="ltr">A cardiovascular outcomes study (DECLARE) was conducted with dapagliflozin 10&nbsp;mg compared with placebo in 17,160&nbsp;patients with type&nbsp;2 diabetes mellitus with or without established cardiovascular disease to evaluate the effect on cardiovascular and renal events.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Glycaemic control</u></em></p><p dir="ltr"><em>Monotherapy</em></p><p dir="ltr">A double‑blind, placebo-controlled study of 24‑week duration (with an additional extension period) was conducted to evaluate the safety and efficacy of monotherapy with Forxiga in subjects with inadequately controlled type&nbsp;2 diabetes mellitus. Once-daily treatment with dapagliflozin resulted in statistically significant (p&nbsp;&lt;&nbsp;0.0001) reductions in HbA1c compared to placebo (Table&nbsp;2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the extension period, HbA1c reductions were sustained through week&nbsp;102 (‑0.61%, and ‑0.17%&nbsp;adjusted mean change from baseline for dapagliflozin&nbsp;10&nbsp;mg and placebo, respectively).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table&nbsp;2. Results at week&nbsp;24 (LOCF<sup>a</sup>) of a placebo‑controlled study of dapagliflozin as monotherapy</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:99%"><tbody><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Monotherapy </strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Dapagliflozin</strong></p><p><strong>10&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>N<sup>b</sup></strong></p></td><td style="vertical-align:top"><p>70</p></td><td style="vertical-align:top"><p>75</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p><p><strong>Baseline (mean)</strong></p><p>Change from baseline<sup>c</sup></p><p>Difference from placebo<sup>c</sup></p><p>&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.01</p><p>‑0.89</p><p>‑0.66<sup>*</sup></p><p>(‑0.96, ‑0.36)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7.79</p><p>‑0.23</p><p>&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Subjects (%) achieving:</strong></p><p><strong>HbA1c &lt;&nbsp;7%</strong></p><p>Adjusted for baseline</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>50.8<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>31.6</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body weight (kg)</strong></p><p>Baseline (mean)</p><p>Change from baseline<sup>c</sup></p><p>Difference from placebo<sup>c</sup></p><p>&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>94.13</p><p>‑3.16</p><p>‑0.97</p><p>(‑2.20, 0.25)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>88.77</p><p>‑2.19</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup>LOCF: Last observation (prior to rescue for rescued subjects) carried forward</p><p><sup>b</sup>All randomised subjects who took at least one dose of double-blind study medicinal product during the short‑term double‑blind period</p><p><sup>c</sup>Least squares mean adjusted for baseline value</p><p><sup>*</sup>p‑value&nbsp;&lt;&nbsp;0.0001 versus placebo</p><p><sup>&sect;</sup>Not evaluated for statistical significance as a result of the sequential testing procedure for secondary end points</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Add-on combination therapy</em></p><p dir="ltr">In a 52‑week, active-controlled non-inferiority study (with 52‑ and 104-week extension periods), Forxiga was evaluated as add‑on therapy to metformin compared with a sulphonylurea (glipizide) as add‑on therapy to metformin in subjects with inadequate glycaemic control (HbA1c&nbsp;&gt;&nbsp;6.5% and &le;&nbsp;10%). The results showed a similar mean reduction in HbA1c from baseline to week&nbsp;52, compared to glipizide, thus demonstrating non‑inferiority (Table&nbsp;3). At week&nbsp;104, adjusted mean change from baseline in HbA1c was ‑0.32% for dapagliflozin and ‑0.14% for glipizide. At week&nbsp;208, adjusted mean change from baseline in HbA1c was ‑0.10% for dapagliflozin and 0.20% for glipizide. At 52, 104 and 208&nbsp;weeks, a significantly lower proportion of subjects in the group treated with dapagliflozin (3.5%, 4.3% and 5.0%, respectively) experienced at least one event of hypoglycaemia compared to the group treated with glipizide (40.8%, 47.0% and 50.0%, respectively). The proportion of subjects remaining in the study at week&nbsp;104 and week 208 was 56.2% and 39.7% for the group treated with dapagliflozin&nbsp;and 50.0% and 34.6% for the group treated with glipizide.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table&nbsp;3. Results at week&nbsp;52 (LOCF<sup>a</sup>) in an active‑controlled study comparing dapagliflozin to glipizide as add‑on to metformin</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:88%"><thead><tr><td style="vertical-align:bottom"><p>Parameter</p></td><td style="vertical-align:top"><p><strong>Dapagliflozin</strong></p><p><strong>+&nbsp;metformin</strong></p></td><td style="vertical-align:top"><p><strong>Glipizide</strong></p><p><strong>+&nbsp;metformin</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>N</strong><sup>b</sup></p></td><td style="vertical-align:top"><p>400</p></td><td style="vertical-align:top"><p>401</p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p><p>Baseline (mean)</p><p>Change from baseline<sup>c</sup></p><p>Difference from glipizide&nbsp;+&nbsp;metformin<sup>c</sup></p><p>&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7.69</p><p>‑0.52</p><p>0.00<sup>d</sup></p><p>(‑0.11, 0.11)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7.74</p><p>‑0.52</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body weight (kg)</strong></p><p>Baseline (mean)</p><p>Change from baseline<sup>c</sup></p><p>Difference from glipizide&nbsp;+&nbsp;metformin<sup>c</sup></p><p>&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>88.44</p><p>‑3.22</p><p>‑4.65<sup>*</sup></p><p>(‑5.14, ‑4.17)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>87.60</p><p>1.44</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>LOCF: Last observation carried forward</p><p><sup>b</sup>Randomised and treated subjects with baseline and at least 1&nbsp;post‑baseline efficacy measurement</p><p><sup>c</sup>Least squares mean adjusted for baseline value</p><p><sup>d</sup>Non‑inferior to glipizide&nbsp;+&nbsp;metformin</p><p><sup>*</sup>p‑value&nbsp;&lt;&nbsp;0.0001</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">Dapagliflozin as an add‑on with either metformin, glimepiride, metformin and a sulphonylurea, sitagliptin (with or without metformin) or insulin resulted in statistically significant reductions in HbA1c at 24&nbsp;weeks compared with subjects receiving placebo (p&nbsp;&lt;&nbsp;0.0001; Tables&nbsp;4, 5 and&nbsp;6).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The reductions in HbA1c observed at week&nbsp;24 were sustained in add‑on combination studies (glimepiride and insulin) with 48‑week data (glimepiride) and up to 104‑week data (insulin). At week&nbsp;48 when added to sitagliptin (with or without metformin), the adjusted mean change from baseline for dapagliflozin&nbsp;10&nbsp;mg and placebo was ‑0.30% and 0.38%, respectively. For the add‑on to metformin study, HbA1c reductions were sustained through week&nbsp;102 (‑0.78% and 0.02% adjusted mean change from baseline for 10&nbsp;mg and placebo, respectively). At week&nbsp;104 for insulin (with or without additional oral glucose‑lowering medicinal products), the HbA1c reductions were ‑0.71% and ‑0.06% adjusted mean change from baseline for dapagliflozin&nbsp;10&nbsp;mg and placebo, respectively. At weeks&nbsp;48 and 104, the insulin dose remained stable compared to baseline in subjects treated with dapagliflozin&nbsp;10&nbsp;mg at an average dose of 76&nbsp;IU/day. In the placebo group there was a mean increase of 10.5&nbsp;IU/day and 18.3&nbsp;IU/day from baseline (mean average dose of 84 and 92&nbsp;IU/day) at weeks&nbsp;48 and 104, respectively. The proportion of subjects remaining in the study at week&nbsp;104 was 72.4% for the group treated with dapagliflozin&nbsp;10&nbsp;mg and 54.8% for the placebo group.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table&nbsp;4. Results of 24‑week (LOCF<sup>a</sup>) placebo-controlled studies of dapagliflozin in add‑on combination with metformin or sitagliptin (with or without metformin)</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:105%"><thead><tr><td rowspan="2" style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>Add‑on combination</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metformin</strong><sup>1</sup></p></td><td colspan="2" style="vertical-align:top"><p><strong>DPP-4 inhibitor</strong></p><p><strong>(sitagliptin</strong><sup>2</sup>)<strong> &plusmn;&nbsp;metformin</strong><sup>1</sup><strong> </strong></p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dapagliflozin</strong></p><p><strong>10&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Dapagliflozin</strong></p><p><strong>10&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong><sup>b</sup></p></td><td style="vertical-align:top"><p>135</p></td><td style="vertical-align:top"><p>137</p></td><td style="vertical-align:top"><p>223</p></td><td style="vertical-align:top"><p>224</p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p><p>Baseline (mean)</p><p>Change from</p><p>&nbsp; baseline<sup>c</sup></p><p>Difference from</p><p>&nbsp; placebo<sup>c</sup></p><p>&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7.92</p><p>&nbsp;</p><p>‑0.84</p><p>&nbsp;</p><p>‑0.54<sup>*</sup></p><p>(‑0.74, ‑0.34)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.11</p><p>&nbsp;</p><p>‑0.30</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7.90</p><p>&nbsp;</p><p>‑0.45</p><p>&nbsp;</p><p>‑0.48<sup>*</sup></p><p>(‑0.62, ‑0.34)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7.97</p><p>&nbsp;</p><p>0.04</p></td></tr><tr><td style="vertical-align:top"><p><strong>Subjects (%) achieving:</strong></p><p><strong>HbA1c &lt;&nbsp;7%</strong></p><p>Adjusted for baseline</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>40.6<sup>**</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>25.9</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body weight (kg)</strong></p><p>Baseline (mean)</p><p>Change from</p><p>&nbsp; baseline<sup>c</sup></p><p>Difference from</p><p>&nbsp; placebo<sup>c</sup></p><p>&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>86.28</p><p>&nbsp;</p><p>‑2.86</p><p>&nbsp;</p><p>‑1.97<sup>*</sup></p><p>(‑2.63, ‑1.31)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>87.74</p><p>&nbsp;</p><p>‑0.89</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>91.02</p><p>&nbsp;</p><p>‑2.14</p><p>&nbsp;</p><p>‑1.89<sup>*</sup></p><p>(‑2.37, ‑1.40)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>89.23</p><p>&nbsp;</p><p>‑0.26</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>1</sup>Metformin &ge;&nbsp;1500&nbsp;mg/day;</p><p><sup>2</sup>sitagliptin 100&nbsp;mg/day</p><p><sup>a</sup>LOCF: Last observation (prior to rescue for rescued subjects) carried forward</p><p><sup>b</sup>All randomised subjects who took at least one dose of double-blind study medicinal product during the short‑term double‑blind period</p><p><sup>c</sup>Least squares mean adjusted for baseline value</p><p><sup>*</sup>p‑value&nbsp;&lt;&nbsp;0.0001 versus placebo&nbsp;+&nbsp;oral glucose‑lowering medicinal product</p><p><sup>**</sup>p‑value&nbsp;&lt;&nbsp;0.05 versus placebo&nbsp;+&nbsp;oral glucose‑lowering medicinal product</p><p><sup>&nbsp;</sup></p></td></tr></thead></table><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table&nbsp;5. Results of 24‑week placebo-controlled studies of dapagliflozin in add‑on combination with sulphonylurea (glimepiride) or metformin and a sulphonylurea</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:105%"><thead><tr><td rowspan="2" style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>Add‑on combination</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Sulphonylurea</strong></p><p><strong>(glimepiride</strong><sup>1</sup><strong>)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Sulphonylurea</strong></p><p><strong>+&nbsp;metformin</strong><sup>2</sup></p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dapagliflozin</strong></p><p><strong>10&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Dapagliflozin</strong></p><p><strong>10&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong><sup>a</sup></p></td><td style="vertical-align:top"><p>151</p></td><td style="vertical-align:top"><p>145</p></td><td style="vertical-align:top"><p>108</p></td><td style="vertical-align:top"><p>108</p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong><sup>b</sup></p><p>Baseline (mean)</p><p>Change from baseline<sup>c</sup></p><p>Difference from placebo<sup>c</sup></p><p>&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.07</p><p>‑0.82</p><p>‑0.68<sup>*</sup></p><p>(‑0.86, ‑0.51)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.15</p><p>‑0.13</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.08</p><p>‑0.86</p><p>&minus;0.69<sup>*</sup><br />(&minus;0.89, &minus;0.49)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.24</p><p>‑0.17</p></td></tr><tr><td style="vertical-align:top"><p><strong>Subjects (%) achieving:</strong></p><p><strong>HbA1c &lt;&nbsp;7% (LOCF)</strong><sup>d</sup></p><p>Adjusted for baseline</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>31.7<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>13.0</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>31.8<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>11.1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body weight (kg) (LOCF)</strong><sup>d</sup></p><p>Baseline (mean)</p><p>Change from baseline<sup>c</sup></p><p>Difference from placebo<sup>c</sup></p><p>&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>80.56</p><p>‑2.26</p><p>‑1.54<sup>*</sup></p><p>(‑2.17, ‑0.92)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>80.94</p><p>‑0.72</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>88.57</p><p>‑2.65</p><p>&minus;2.07<sup>*</sup><br />(&minus;2.79, &minus;1.35)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>90.07</p><p>-0.58</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>1</sup>glimepiride 4&nbsp;mg/day;</p><p><sup>2</sup>Metformin (immediate- or extended-release formulations) &ge;1500 mg/day plus maximum tolerated dose, which must be at least half maximum dose, of a sulphonylurea for at least 8 weeks prior to enrolment.</p><p><sup>aRandomised and treated patients with baseline and at least 1 post-baseline efficacy measurement.</sup></p><p><sup>b</sup>Columns 1 and 2, HbA1c analysed using LOCF (see footnote d); Columns 3 and 4, HbA1c analysed using LRM (see footnote e)</p><p><sup>c</sup>Least squares mean adjusted for baseline value</p><p><sup>d</sup>LOCF: Last observation (prior to rescue for rescued subjects) carried forward</p><p>eLRM: Longitudinal repeated measures analysis</p><p><sup>*</sup>p‑value&nbsp;&lt;&nbsp;0.0001 versus placebo&nbsp;+&nbsp;oral glucose‑lowering medicinal product(s)</p><p><sup>&nbsp;</sup></p></td></tr></thead></table><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table&nbsp;6. Results at week&nbsp;24 (LOCF<sup>a</sup>) in a placebo-controlled study of dapagliflozin in combination with insulin (alone or with oral glucose-lowering medicinal products)</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:100%"><thead><tr><td style="vertical-align:bottom"><p>Parameter</p></td><td style="vertical-align:top"><p><strong>Dapagliflozin 10&nbsp;mg</strong></p><p><strong>+&nbsp;insulin</strong></p><p><strong>&plusmn;&nbsp;oral glucose‑lowering medicinal products</strong><sup>2</sup></p></td><td style="vertical-align:bottom"><p><strong>Placebo</strong></p><p><strong>+&nbsp;insulin</strong></p><p><strong>&plusmn;&nbsp;oral glucose‑lowering medicinal products</strong><sup>2</sup></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>N</strong><sup>b</sup></p></td><td style="vertical-align:top"><p>194</p></td><td style="vertical-align:top"><p>193</p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p><p>Baseline (mean)</p><p>Change from baseline<sup>c</sup></p><p>Difference from placebo<sup>c</sup></p><p>&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.58</p><p>‑0.90</p><p>‑0.60<sup>*</sup></p><p>(‑0.74, ‑0.45)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.46</p><p>‑0.30</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body weight (kg)</strong></p><p>Baseline (mean)</p><p>Change from baseline<sup>c</sup></p><p>Difference from placebo<sup>c</sup></p><p>&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>94.63</p><p>‑1.67</p><p>‑1.68<sup>*</sup></p><p>(‑2.19, ‑1.18)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>94.21</p><p>0.02</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mean daily insulin dose (IU)</strong><sup>1</sup></p><p>Baseline (mean)</p><p>Change from baseline<sup>c</sup></p><p>Difference from placebo<sup>c</sup></p><p>&nbsp;&nbsp;&nbsp; (95%&nbsp;CI)</p><p>Subjects with mean daily insulin dose reduction of at least 10%&nbsp;(%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>77.96</p><p>‑1.16</p><p>‑6.23<sup>*</sup></p><p>(‑8.84, ‑3.63)</p><p>&nbsp;</p><p>&nbsp;</p><p>19.7<sup>**</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>73.96</p><p>5.08</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>11.0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>LOCF: Last observation (prior to or on the date of the first insulin up-titration, if needed) carried forward</p><p><sup>b</sup>All randomised subjects who took at least one dose of double-blind study medicinal product during the short-term double‑blind period</p><p><sup>c</sup>Least squares mean adjusted for baseline value and presence of oral glucose-lowering medicinal product</p><p><sup>*</sup>p‑value&nbsp;&lt;&nbsp;0.0001 versus placebo&nbsp;+&nbsp;insulin&nbsp;&plusmn;&nbsp;oral glucose‑lowering medicinal product</p><p><sup>**</sup>p‑value&nbsp;&lt;&nbsp;0.05 versus placebo&nbsp;+&nbsp;insulin&nbsp;&plusmn;&nbsp;oral glucose‑lowering medicinal product</p><p><sup>1</sup>Up‑titration of insulin regimens (including short-acting, intermediate, and basal insulin) was only allowed if subjects met pre‑defined FPG criteria.</p><p><sup>2</sup>Fifty&nbsp;percent of subjects were on insulin monotherapy at baseline; 50% were on 1 or 2&nbsp;oral glucose‑lowering medicinal product(s) in addition to insulin: Of this latter group, 80% were on metformin alone, 12% were on metformin plus sulphonylurea therapy, and the rest were on other oral glucose‑lowering medicinal products.</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr"><em>In combination with metformin in drug-naive patients</em></p><p dir="ltr">A total of 1,236&nbsp;drug-naive patients with inadequately controlled type&nbsp;2 diabetes (HbA1c&nbsp;&ge;&nbsp;7.5% and &le;&nbsp;12%) participated in two active-controlled studies of 24&nbsp;weeks duration to evaluate the efficacy and safety of dapagliflozin (5&nbsp;mg or 10&nbsp;mg) in combination with metformin in drug-naive patients versus therapy with the monocomponents.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Treatment with dapagliflozin 10&nbsp;mg in combination with metformin (up to 2000&nbsp;mg per day) provided significant improvements in HbA1c compared to the individual components (Table&nbsp;7), and led to greater reductions in fasting plasma glucose (FPG) (compared to the individual components) and body weight (compared to metformin).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table 7. Results at week 24 (LOCF<sup>a</sup>) in an active-controlled study of dapagliflozin and metformin combination therapy in drug-naive patients</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:98%"><thead><tr><td style="vertical-align:bottom"><p>Parameter</p></td><td style="vertical-align:top"><p><strong>Dapagliflozin 10 mg +</strong></p><p><strong>metformin</strong></p></td><td style="vertical-align:top"><p><strong>Dapagliflozin 10 mg</strong></p></td><td style="vertical-align:top"><p><strong>Metformin</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>N</strong><sup>b</sup></p></td><td style="vertical-align:top"><p>211<sup>b</sup></p></td><td style="vertical-align:top"><p>219<sup>b</sup></p></td><td style="vertical-align:top"><p>208<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p><p>Baseline (mean)</p><p>Change from baseline<sup>c</sup></p><p>Difference from dapagliflozin<sup>c</sup></p><p>&nbsp;&nbsp;&nbsp; (95% CI)</p><p>Difference from metformin<sup>c</sup></p><p>&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>9.10</p><p>‑1.98</p><p>&minus;0.53<sup>*</sup></p><p>(&minus;0.74, &minus;0.32)</p><p>&minus;0.54<sup>*</sup></p><p>(&minus;0.75, &minus;0.33)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>9.03</p><p>‑1.45</p><p>&nbsp;</p><p>&nbsp;</p><p>&minus;0.01</p><p>(&minus;0.22, 0.20)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>9.03</p><p>‑1.44</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup>LOCF: last observation (prior to rescue for rescued patients) carried forward.</p><p><sup>b</sup>All randomised patients who took at least one dose of double-blind study medicinal product during the short-term double-blind period.</p><p><sup>c</sup>Least squares mean adjusted for baseline value.</p><p><sup>*</sup>p-value &lt;0.0001.</p></td></tr></tbody></table><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>Combination therapy with prolonged‑release exenatide</em></p><p dir="ltr">In a 28‑week, double‑blind, active comparator‑controlled study, the combination of dapagliflozin and prolonged‑release exenatide (a GLP‑1 receptor agonist) was compared to dapagliflozin alone and prolonged‑release exenatide alone in subjects with inadequate glycaemic control on metformin alone (HbA1c&nbsp;&ge;&nbsp;8% and &le;&nbsp;12%). All treatment groups had a reduction in HbA1c compared to baseline. The combination treatment with dapagliflozin 10&nbsp;mg and prolonged‑release exenatide group showed superior reductions in HbA1c from baseline compared to dapagliflozin alone and prolonged‑release exenatide alone (Table&nbsp;8).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table&nbsp;8. Results of one 28‑week study of dapagliflozin and prolonged‑release exenatide versus dapagliflozin alone and prolonged‑release exenatide alone, in combination with metformin (intent to treat patients)</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:bottom"><p><strong>Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Dapagliflozin 10&nbsp;mg QD</strong></p><p><strong>+</strong></p><p><strong>prolonged-release exenatide 2&nbsp;mg QW</strong></p></td><td style="vertical-align:top"><p><strong>Dapagliflozin 10&nbsp;mg QD</strong></p><p><strong>+</strong></p><p><strong>placebo QW</strong></p></td><td style="vertical-align:top"><p><strong>Prolonged-release exenatide 2&nbsp;mg QW</strong></p><p><strong>+</strong></p><p><strong>placebo QD</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td><p><strong>228</strong></p></td><td><p><strong>230</strong></p></td><td><p><strong>227</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td><p>9.29</p></td><td><p>9.25</p></td><td><p>9.26</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline<sup>a</sup></p></td><td><p>‑1.98</p></td><td><p>‑1.39</p></td><td><p>‑1.60</p></td></tr><tr><td><p>Mean difference in change from baseline between combination and single medicinal product (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>‑0.59*</p><p>(‑0.84, ‑0.34)</p></td><td><p>‑0.38**</p><p>(‑0.63, ‑0.13)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Subjects (%) achieving HbA1c<sub> </sub></strong>&lt; <strong>7%</strong></p></td><td><p>44.7</p></td><td><p>19.1</p></td><td><p>26.9</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body weight (kg)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td><p>92.13</p></td><td><p>90.87</p></td><td><p>89.12</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline<sup> a</sup></p></td><td><p>‑3.55</p></td><td><p>‑2.22</p></td><td><p>‑1.56</p></td></tr><tr><td><p>Mean difference in change from baseline between combination and single medicinal product (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>‑1.33*</p><p>(‑2.12, ‑0.55)</p></td><td><p>‑2.00*</p><p>(‑2.79, ‑1.20)</p></td></tr><tr><td colspan="4"><p>QD=once daily, QW=once weekly, N=number of patients, CI=confidence interval.</p><p><sup>a</sup>Adjusted least squares means (LS Means) and treatment group difference(s) in the change from baseline values at week 28 are modelled using a mixed model with repeated measures (MMRM) including treatment, region, baseline HbA1c stratum (&lt;&nbsp;9.0% or &ge;&nbsp;9.0%), week, and treatment by week interaction as fixed factors, and baseline value as a covariate.</p><p><sup>*</sup>p&nbsp;&lt;&nbsp;0.001, <sup>**</sup>p&nbsp;&lt;&nbsp;0.01.</p><p>P‑values are all adjusted p‑values for multiplicity.</p><p>Analyses exclude measurements post rescue therapy and post premature discontinuation of study medicinal product.</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Fasting plasma glucose</u></em></p><p dir="ltr">Treatment with dapagliflozin&nbsp;10&nbsp;mg as a monotherapy or as an add‑on to either metformin, glimepiride, metformin and a sulphonylurea, sitagliptin (with or without metformin) or insulin resulted in statistically significant reductions in FPG (-1.90&nbsp;to&nbsp;‑1.20&nbsp;mmol/L [‑34.2&nbsp;to&nbsp;‑21.7&nbsp;mg/dL]) compared to placebo (‑0.33&nbsp;to&nbsp;0.21&nbsp;mmol/L [‑6.0&nbsp;to&nbsp;3.8&nbsp;mg/dL]). This effect was observed at week&nbsp;1 of treatment and maintained in studies extended through week&nbsp;104.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Combination therapy of dapagliflozin 10&nbsp;mg and prolonged‑release exenatide resulted in significantly greater reductions in FPG at week&nbsp;28: ‑3.66&nbsp;mmol/L (‑65.8&nbsp;mg/dL), compared to ‑2.73&nbsp;mmol/L (‑49.2&nbsp;mg/dL) for dapagliflozin alone (p&nbsp;&lt;&nbsp;0.001) and ‑2.54&nbsp;mmol/L (‑45.8&nbsp;mg/dL) for exenatide alone (p&nbsp;&lt;&nbsp;0.001).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In a dedicated study in diabetic patients with an eGFR&nbsp;&ge;&nbsp;45 to &lt;&nbsp;60 mL/min/1.73&nbsp;m<sup>2</sup>, treatment with dapagliflozin demonstrated reductions in FPG at week&nbsp;24: -1.19&nbsp;mmol/L (‑21.46&nbsp;mg/dL) compared to -0.27&nbsp;mmol/L (‑4.87&nbsp;mg/dL) for placebo (p=0.001).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Post‑prandial glucose</u></em></p><p dir="ltr">Treatment with dapagliflozin&nbsp;10&nbsp;mg as an add‑on to glimepiride resulted in statistically significant reductions in 2‑hour post‑prandial glucose at 24&nbsp;weeks that were maintained up to week&nbsp;48.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Treatment with dapagliflozin&nbsp;10&nbsp;mg as an add‑on to sitagliptin (with or without metformin) resulted in reductions in 2‑hour post‑prandial glucose at 24&nbsp;weeks that were maintained up to week&nbsp;48.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Combination therapy of dapagliflozin 10&nbsp;mg and prolonged‑release exenatide resulted in significantly greater reductions in 2‑hour post‑prandial glucose at week&nbsp;28 compared to either medicinal product alone.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Body weight</u></em><u> </u></p><p dir="ltr">Dapagliflozin 10&nbsp;mg as an add‑on to metformin, glimepiride, metformin and a sulphonylurea, sitagliptin (with or without metformin) or insulin resulted in statistically significant body weight reduction at 24&nbsp;weeks (p&nbsp;&lt;&nbsp;0.0001, Tables&nbsp;4 and&nbsp;5). These effects were sustained in longer‑term studies. At 48&nbsp;weeks, the difference for dapagliflozin as add‑on to sitagliptin (with or without metformin) compared with placebo was ‑2.22&nbsp;kg. At 102&nbsp;weeks, the difference for dapagliflozin as add‑on to metformin compared with placebo, or as add‑on to insulin compared with placebo was ‑2.14 and ‑2.88&nbsp;kg, respectively.</p><p dir="ltr">&nbsp;</p><p dir="ltr">As an add‑on therapy to metformin in an active‑controlled non‑inferiority study, dapagliflozin resulted in a statistically significant body weight reduction compared with glipizide of ‑4.65&nbsp;kg at 52&nbsp;weeks (p&nbsp;&lt;&nbsp;0.0001, Table&nbsp;3) that was sustained at 104 and 208&nbsp;weeks (‑5.06&nbsp;kg and &ndash;4.38&nbsp;kg, respectively).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The combination of dapagliflozin 10&nbsp;mg and prolonged‑release exenatide demonstrated significantly greater weight reductions compared to either medicinal product alone (Table&nbsp;8).</p><p dir="ltr">&nbsp;</p><p dir="ltr">A 24‑week study in 182&nbsp;diabetic subjects using dual energy X‑ray absorptiometry (DXA) to evaluate body composition demonstrated reductions with dapagliflozin&nbsp;10&nbsp;mg plus metformin compared with placebo plus metformin, respectively, in body weight and body fat mass as measured by DXA rather than lean tissue or fluid loss. Treatment with Forxiga plus metformin showed a numerical decrease in visceral adipose tissue compared with placebo plus metformin treatment in a magnetic resonance imaging substudy.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Blood pressure</u></em></p><p dir="ltr">In a pre‑specified pooled analysis of 13&nbsp;placebo-controlled studies, treatment with dapagliflozin&nbsp;10&nbsp;mg resulted in a systolic blood pressure change from baseline of &ndash;3.7&nbsp;mmHg and diastolic blood pressure of &ndash;1.8&nbsp;mmHg versus &ndash;0.5&nbsp;mmHg systolic and ‑0.5&nbsp;mmHg diastolic blood pressure for placebo group at week&nbsp;24. Similar reductions were observed up to 104&nbsp;weeks.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Combination therapy of dapagliflozin 10&nbsp;mg and prolonged‑release exenatide resulted in a significantly greater reduction in systolic blood pressure at week&nbsp;28 (‑4.3&nbsp;mmHg) compared to dapagliflozin alone (‑1.8&nbsp;mmHg, p&nbsp;&lt;&nbsp;0.05) and prolonged‑release exenatide alone (‑1.2&nbsp;mmHg, p&nbsp;&lt;&nbsp;0.01).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In two 12‑week, placebo-controlled studies a total of 1,062&nbsp;patients with inadequately controlled type&nbsp;2 diabetes and hypertension (despite pre-existing stable treatment with an ACE-I or ARB in one study and an ACE-I or ARB plus one additional antihypertensive treatment in another study) were treated with dapagliflozin 10&nbsp;mg or placebo. At week 12 for both studies, dapagliflozin 10&nbsp;mg plus usual antidiabetic treatment provided improvement in HbA1c and decreased the placebo-corrected systolic blood pressure on average by 3.1 and 4.3&nbsp;mmHg, respectively.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In a dedicated study in diabetic patients with an eGFR&nbsp;&ge;&nbsp;45 to &lt;&nbsp;60&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>, treatment with dapagliflozin demonstrated reductions in seated systolic blood pressure at week&nbsp;24: ‑4.8&nbsp;mmHg compared to ‑1.7&nbsp;mmHg for placebo (p<strong>&nbsp;</strong>&lt;&nbsp;0.05).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Glycaemic control in patients with moderate renal impairment CKD 3A (eGFR&nbsp;&ge;&nbsp;45&nbsp;to&nbsp;&lt;&nbsp;60&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>)</u></em></p><p dir="ltr">The efficacy of dapagliflozin was assessed in a dedicated study in diabetic patients with an eGFR&nbsp;&ge;&nbsp;45 to &lt;&nbsp;60&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> who had inadequate glycaemic control on usual care. Treatment with dapagliflozin resulted in reductions in HbA1c and body weight compared with placebo (Table&nbsp;9).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table 9. Results at week&nbsp;24 of a placebo‑controlled study of dapagliflozin in diabetic patients with an eGFR&nbsp;&ge;&nbsp;45 to &lt;&nbsp;60&nbsp;mL/min/1.73&nbsp;m<sup>2</sup></strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:99%"><tbody><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Dapagliflozin</strong><sup>a</sup></p><p><strong>10&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong><sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>N<sup>b</sup></strong></p></td><td style="vertical-align:top"><p><strong>159</strong></p></td><td style="vertical-align:top"><p><strong>161</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>8.35</p></td><td style="vertical-align:top"><p>8.03</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline<sup>b</sup></p></td><td style="vertical-align:top"><p>‑0.37</p></td><td style="vertical-align:top"><p>‑0.03</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo<sup>b</sup></p><p>&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>‑0.34*</p><p>(‑0.53, ‑0.15)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body weight (kg)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>92.51</p></td><td style="vertical-align:top"><p>88.30</p></td></tr><tr><td style="vertical-align:top"><p>Percent change from baseline<sup>c</sup></p></td><td style="vertical-align:top"><p>-3.42</p></td><td style="vertical-align:top"><p>-2.02</p></td></tr><tr><td style="vertical-align:top"><p>Difference in percent change from placebo<sup>c</sup></p><p>&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>-1.43*</p><p>(-2.15, -0.69)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup> Metformin or metformin hydrochloride were part of the usual care in 69.4% and 64.0% of the patients for the dapagliflozin and placebo groups, respectively.</p><p><sup>b</sup> Least squares mean adjusted for baseline value</p><p><sup>c </sup>Derived from least squares mean adjusted for baseline value</p><p><sup>*</sup> p&lt;0.001</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Patients with baseline HbA1c&nbsp;&ge;&nbsp;9%</u></em></p><p dir="ltr">In a pre‑specified analysis of subjects with baseline HbA1c&nbsp;&ge;&nbsp;9.0%, treatment with dapagliflozin&nbsp;10&nbsp;mg resulted in statistically significant reductions in HbA1c at week&nbsp;24 as a monotherapy (adjusted mean change from baseline: ‑2.04% and 0.19% for dapagliflozin&nbsp;10&nbsp;mg and placebo, respectively) and as an add‑on to metformin (adjusted mean change from baseline: ‑1.32% and ‑0.53% for dapagliflozin and placebo, respectively).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Cardiovascular and renal outcomes</u></em></p><p dir="ltr">Dapagliflozin Effect on Cardiovascular Events (DECLARE) was an international, multicentre, randomised, double-blind, placebo-controlled clinical study conducted to determine the effect of dapagliflozin compared with placebo on cardiovascular outcomes when added to current background therapy. All patients had type&nbsp;2 diabetes mellitus and either at least two additional cardiovascular risk factors (age&nbsp;&ge;&nbsp;55&nbsp;years in men or &ge;&nbsp;60&nbsp;years in women and one or more of dyslipidaemia, hypertension or current tobacco use) or established cardiovascular disease.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Of 17,160&nbsp;randomised patients, 6,974&nbsp;(40.6%) had established cardiovascular disease and 10,186&nbsp;(59.4%) did not have established cardiovascular disease. 8,582&nbsp;patients were randomised to dapagliflozin 10&nbsp;mg and 8,578 to placebo, and were followed for a median of 4.2&nbsp;years.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The mean age of the study population was 63.9&nbsp;years, 37.4% were female. In total, 22.4% had had diabetes for &le;&nbsp;5&nbsp;years, mean duration of diabetes was 11.9&nbsp;years. Mean HbA1c was 8.3% and mean BMI was 32.1&nbsp;kg/m2.</p><p dir="ltr">&nbsp;</p><p dir="ltr">At baseline, 10.0% of patients had a history of heart failure. Mean eGFR was 85.2&nbsp;mL/min/1.73&nbsp;m2, 7.4% of patients had eGFR&nbsp;&lt;&nbsp;60&nbsp;mL/min/1.73&nbsp;m2, and 30.3% of patients had micro- or macroalbuminuria (urine albumin to creatinine ratio [UACR]&nbsp;&ge;&nbsp;30 to &le;&nbsp;300&nbsp;mg/g or &gt;&nbsp;300&nbsp;mg/g, respectively).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Most patients (98%) used one or more diabetic medicinal products at baseline, including metformin (82%), insulin (41%) and sulfonylurea (43%).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The primary endpoints were time to first event of the composite of cardiovascular death, myocardial infarction or ischaemic stroke (MACE) and time to first event of the composite of hospitalisation for heart failure or cardiovascular death. The secondary endpoints were a renal composite endpoint and all-cause mortality.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Major adverse cardiovascular events</em></p><p dir="ltr">Dapagliflozin 10&nbsp;mg demonstrated non-inferiority versus placebo for the composite of cardiovascular death, myocardial infarction or ischaemic stroke (one-sided p&nbsp;&lt;&nbsp;0.001).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Heart failure or cardiovascular death</em></p><p dir="ltr">Dapagliflozin 10&nbsp;mg demonstrated superiority versus placebo in preventing the composite of hospitalisation for heart failure or cardiovascular death (Figure&nbsp;1). The difference in treatment effect was driven by hospitalisation for heart failure, with no difference in cardiovascular death (Figure&nbsp;2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The treatment benefit of dapagliflozin over placebo was observed both in patients with and without established cardiovascular disease, with and without heart failure at baseline, and was consistent across key subgroups, including age, gender, renal function (eGFR) and region.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Figure 1: Time to first occurrence of hospitalisation for heart failure or cardiovascular death</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients at risk is the number of patients at risk at the beginning of the period.</p><p dir="ltr">HR=Hazard ratio CI=Confidence interval.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Results on primary and secondary endpoints are displayed in Figure&nbsp;2. Superiority of dapagliflozin over placebo was not demonstrated for MACE (p=0.172). The renal composite endpoint and all-cause mortality were therefore not tested as part of the confirmatory testing procedure.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Figure 2: Treatment effects for the primary composite endpoints and their components, and the secondary endpoints and components</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">Renal composite endpoint defined as: sustained confirmed &ge;&nbsp;40% decrease in eGFR to eGFR &lt;60&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> and/or end-stage kidney disease (dialysis &ge;&nbsp;90 days or kidney transplantation, sustained confirmed eGFR &lt;&nbsp;15&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>) and/or renal or cardiovascular death.</p><p dir="ltr">p-values are two-sided. p-values for the secondary endpoints and for single components are nominal. Time to first event was analysed in a Cox proportional hazards model. The number of first events for the single components are the actual number of first events for each component and does not add up to the number of events in the composite endpoint.</p><p dir="ltr">CI=confidence interval.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Nephropathy</em></p><p dir="ltr">Dapagliflozin reduced the incidence of events of the composite of confirmed sustained eGFR decrease, end-stage kidney disease, renal or cardiovascular death. The difference between groups was driven by reductions in events of the renal components; sustained eGFR decrease, end-stage kidney disease and renal death (Figure&nbsp;2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The hazard ratio (HR) for time to nephropathy (sustained eGFR decrease, end-stage kidney disease and renal death) was 0.53&nbsp;(95%&nbsp;CI&nbsp;0.43,&nbsp;0.66) for dapagliflozin versus placebo.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In addition, dapagliflozin reduced the new onset of sustained albuminuria (HR&nbsp;0.79 [95%&nbsp;CI&nbsp;0.72,&nbsp;0.87]) and led to greater regression of macroalbuminuria (HR&nbsp;1.82 [95%&nbsp;CI&nbsp;1.51,&nbsp;2.20]) compared with placebo.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Heart failure</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em><u>DAPA-HF study: Heart failure with reduced ejection fraction (LVEF&nbsp;&le;&nbsp;40%)</u></em></p><p dir="ltr">Dapagliflozin And Prevention of Adverse outcomes in Heart Failure (DAPA-HF) was an international, multicentre, randomised, double-blind, placebo-controlled study in patients with heart failure (New York Heart Association [NYHA] functional class II-IV) with reduced ejection fraction (left ventricular ejection fraction [LVEF]&nbsp;&le;&nbsp;40%) to determine the effect of dapagliflozin compared with placebo, when added to background standard of care therapy, on the incidence of cardiovascular death and worsening heart failure.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Of 4,744&nbsp;patients, 2,373 were randomised to dapagliflozin 10&nbsp;mg and 2,371 to placebo and followed for a median of 18&nbsp;months. The mean age of the study population was 66&nbsp;years, 77% were male.</p><p dir="ltr">&nbsp;</p><p dir="ltr">At baseline, 67.5% of the patients were classified as NYHA class&nbsp;II, 31.6% class&nbsp;III and 0.9% class&nbsp;IV, median LVEF was 32%, 56% of the heart failures were ischaemic, 36% were non-ischaemic and 8% were of unknown aetiology. In each treatment group, 42% of the patients had a history of type&nbsp;2 diabetes mellitus, and an additional 3% of the patients in each group were classified as having type&nbsp;2 diabetes mellitus based on a HbA1c&nbsp;&ge;&nbsp;6.5% at both enrolment and randomisation. Patients were on standard of care therapy; 94% of patients were treated with ACE-I, ARB or angiotensin receptor-neprilysin inhibitor (ARNI, 11%), 96% with beta-blocker, 71% with mineralocorticoid receptor antagonist (MRA), 93% with diuretic and 26% had an implantable device.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients with eGFR&nbsp;&ge;&nbsp;30 mL/min/1.73&nbsp;m2 at enrolment were included in the study. The mean eGFR was 66&nbsp;mL/min/1.73&nbsp;m2, 41% of patients had eGFR&nbsp;&lt;&nbsp;60mL/min/1.73&nbsp;m2 and 15% had eGFR&nbsp;&lt;&nbsp;45&nbsp;mL/min/1.73&nbsp;m2.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Cardiovascular death and worsening heart failure</u></em></p><p dir="ltr">Dapagliflozin was superior to placebo in preventing the primary composite endpoint of cardiovascular death, hospitalisation for heart failure or urgent heart failure visit (HR&nbsp;0.74 [95%&nbsp;CI&nbsp;0.65, 0.85], p&nbsp;&lt;&nbsp;0.0001). The effect was observed early and was sustained throughout the duration of the study (Figure&nbsp;3).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Figure 3: Time to first occurrence of the composite of cardiovascular death, hospitalisation for heart failure or urgent heart failure visit</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">An urgent heart failure visit was defined as an urgent, unplanned, assessment by a physician, e.g. in an Emergency Department, and requiring treatment for worsening heart failure (other than just an increase in oral diuretics).</p><p dir="ltr">Patients at risk is the number of patients at risk at the beginning of the period.</p><p dir="ltr">&nbsp;</p><p dir="ltr">All three components of the primary composite endpoint individually contributed to the treatment effect (Figure&nbsp;4). There were few urgent heart failure visits.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Figure 4: Treatment effects for the primary composite endpoint, its components and all-cause mortality</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">An urgent heart failure visit was defined as an urgent, unplanned, assessment by a physician, e.g. in an Emergency Department, and requiring treatment for worsening heart failure (other than just an increase in oral diuretics).</p><p dir="ltr">The number of first events for the single components are the actual number of first events for each component and does not add up to the number of events in the composite endpoint.</p><p dir="ltr">Event rates are presented as the number of subjects with event per 100&nbsp;patient years of follow-up.</p><p dir="ltr">p-values for single components and all-cause mortality are nominal.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Dapagliflozin also reduced the total number of events of hospitalisations for heart failure (first and recurrent) and cardiovascular death; there were 567&nbsp;events in the dapagliflozin group versus 742&nbsp;events in the placebo group (Rate Ratio&nbsp;0.75 [95% CI 0.65, 0.88]; p=0.0002).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The treatment benefit of dapagliflozin was observed in heart failure patients both with type&nbsp;2 diabetes mellitus and without diabetes. Dapagliflozin reduced the primary composite endpoint of incidence of cardiovascular death and worsening heart failure with a HR of 0.75 (95% CI 0.63, 0.90) in patients with diabetes and 0.73 (95% CI 0.60, 0.88) in patients without diabetes.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The treatment benefit of dapagliflozin over placebo on the primary endpoint was also consistent across other key subgroups, including concomitant heart failure therapy, renal function (eGFR), age, gender, and region.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Patient reported outcome &ndash; heart failure symptoms</u></em></p><p dir="ltr">The treatment effect of dapagliflozin on heart failure symptoms was assessed by the Total Symptom Score of the Kansas City Cardiomyopathy Questionnaire (KCCQ-TSS), which quantifies heart failure symptom frequency and severity, including fatigue, peripheral oedema, dyspnoea and orthopnoea. The score ranges from 0 to 100, with higher scores representing better health status.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Treatment with dapagliflozin resulted in a statistically significant and clinically meaningful benefit over placebo in heart failure symptoms, as measured by change from baseline at month&nbsp;8 in the KCCQ-TSS, (Win Ratio&nbsp;1.18 [95% CI 1.11, 1.26]; p&nbsp;&lt;&nbsp;0.0001). Both symptom frequency and symptom burden contributed to the results. Benefit was seen both in improving heart failure symptoms and in preventing deterioration of heart failure symptoms.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In responder analyses, the proportion of patients with a clinically meaningful improvement on the KCCQ-TSS from baseline at 8&nbsp;months, defined as 5&nbsp;points or more, was higher for the dapagliflozin treatment group compared with placebo. The proportion of patients with a clinically meaningful deterioration, defined as 5&nbsp;points or more, was lower for the dapagliflozin treatment group compared to placebo. The benefits observed with dapagliflozin remained when applying more conservative cut-offs for larger clinically meaningful change (Table&nbsp;10).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table 10. Number and percent of patients with clinically meaningful improvement and deterioration on the KCCQ-TSS at 8 months</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:596px"><tbody><tr><td><p><strong>Change from baseline at 8&nbsp;months:</strong></p></td><td style="vertical-align:top"><p><strong>Dapagliflozin<br />10 mg</strong></p><p><strong>n<sup>a</sup>=2086</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>n<sup>a</sup>=2062</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Improvement</em></strong></p></td><td style="vertical-align:top"><p><strong>n (%)<sup> </sup>improved<sup>b</sup></strong></p></td><td style="vertical-align:top"><p><strong>n (%)<sup> </sup>improved<sup>b</sup></strong></p></td><td style="vertical-align:top"><p><strong>Odds ratio<sup>c</sup> (95%&nbsp;CI)</strong></p></td><td style="vertical-align:top"><p><strong>p-value<sup>f</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&ge; 5 points</p></td><td style="vertical-align:top"><p>933 (44.7)</p></td><td style="vertical-align:top"><p>794 (38.5)</p></td><td style="vertical-align:top"><p>1.14<br />(1.06, 1.22)</p></td><td style="vertical-align:top"><p>0.0002</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 10 points</p></td><td style="vertical-align:top"><p>689 (33.0)</p></td><td style="vertical-align:top"><p>579 (28.1)</p></td><td style="vertical-align:top"><p>1.13<br />(1.05, 1.22)</p></td><td style="vertical-align:top"><p>0.0018</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 15 points</p></td><td style="vertical-align:top"><p>474 (22.7)</p></td><td style="vertical-align:top"><p>406 (19.7)</p></td><td style="vertical-align:top"><p>1.10<br />(1.01, 1.19)</p></td><td style="vertical-align:top"><p>0.0300</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Deterioration</em></strong></p></td><td style="vertical-align:top"><p><strong>n (%) deteriorated<sup>d</sup></strong></p></td><td style="vertical-align:top"><p><strong>n (%) deteriorated<sup>d</sup></strong></p></td><td style="vertical-align:top"><p><strong>Odds ratio<sup>e</sup> (95%&nbsp;CI)</strong></p></td><td style="vertical-align:top"><p><strong>p-value<sup>f</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&ge; 5 points</p></td><td style="vertical-align:top"><p>537 (25.7)</p></td><td style="vertical-align:top"><p>693 (33.6)</p></td><td style="vertical-align:top"><p>0.84<br />(0.78, 0.89)</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 10 points</p></td><td style="vertical-align:top"><p>395 (18.9)</p></td><td style="vertical-align:top"><p>506 (24.5)</p></td><td style="vertical-align:top"><p>0.85<br />(0.79, 0.92)</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a</sup> Number of patients with an observed KCCQ-TSS or who died prior to 8 months.</p><p><sup>b</sup> Number of patients who had an observed improvement of at least 5, 10 or 15&nbsp;points from baseline. Patients who died prior to the given timepoint are counted as not improved.</p><p><sup>c</sup> For improvement, an odds ratio &gt; 1 favours dapagliflozin 10 mg.</p><p><sup>d</sup> Number of patients who had an observed deterioration of at least 5 or 10&nbsp;points from baseline. Patients who died prior to the given timepoint are counted as deteriorated.</p><p><sup>e</sup> For deterioration, an odds ratio &lt; 1 favours dapagliflozin 10 mg.</p><p><sup>f</sup> p-values are nominal.</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Nephropathy</em></p><p dir="ltr">There were few events of the renal composite endpoint (confirmed sustained &ge;&nbsp;50% eGFR decrease, ESKD, or renal death); the incidence was 1.2% in the dapagliflozin group and 1.6% in the placebo group.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>DELIVER study: Heart failure with left ventricular ejection fraction &gt; 40%</u></em></p><p dir="ltr">Dapagliflozin Evaluation to Improve the LIVEs of Patients with PReserved Ejection Fraction Heart Failure (DELIVER) was an international, multicentre, randomised, double-blind, placebo-controlled study in patients aged &ge;&nbsp;40&nbsp;years with heart failure (NYHA class&nbsp;II-IV) with LVEF &gt;&nbsp;40% and evidence of structural heart disease, to determine the effect of dapagliflozin compared with placebo on the incidence of cardiovascular death and worsening heart failure.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Of 6,263&nbsp;patients, 3,131 were randomised to dapagliflozin 10&nbsp;mg and 3,132 to placebo and followed for a median of 28&nbsp;months. The study included 654&nbsp;(10%)&nbsp;subacute heart failure patients (defined as randomised during hospitalisation for heart failure or within 30&nbsp;days of discharge). The mean age of the study population was 72&nbsp;years and 56% were male.</p><p dir="ltr">&nbsp;</p><p dir="ltr">At baseline, 75% patients were classified as NYHA class&nbsp;II, 24% class&nbsp;III and 0.3% class&nbsp;IV. Median LVEF was 54%, 34% of the patients had LVEF&nbsp;&le;&nbsp;49%, 36% had LVEF&nbsp;50-59% and 30% had LVEF&nbsp;&ge;&nbsp;60%. In each treatment group, 45% had a history of type&nbsp;2 diabetes mellitus. Baseline therapy included ACEi/ARB/ARNI (77%), beta-blockers (83%) diuretics (98%) and MRA (43%).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients with eGFR &ge;&nbsp;25 mL/min/1.73 m2 at enrolment were included in the study. The mean eGFR was 61&nbsp;mL/min/1.73&nbsp;m2, 49% of patients had eGFR &lt;&nbsp;60mL/min/1.73&nbsp;m2, 23% had eGFR&nbsp;&lt;&nbsp;45&nbsp;mL/min/1.73&nbsp;m2, and 3% had eGFR&nbsp;&lt;&nbsp;30 mL/min/1.73&nbsp;m2.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Cardiovascular death and worsening heart failure</em></p><p dir="ltr">Dapagliflozin was superior to placebo in reducing the incidence of the primary composite endpoint of cardiovascular death, hospitalisation for heart failure or urgent heart failure visit (HR&nbsp;0.82 [95%&nbsp;CI 0.73, 0.92]; p=0.0008). The dapagliflozin and placebo event curves diverged early and the separation was maintained throughout the study (Figure&nbsp;5).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Figure 5: Time to first occurrence of the composite of cardiovascular death, hospitalisation for heart failure or urgent heart failure visit</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">&nbsp;</p><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>Months from randomisation</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>Dapagliflozin vs. Placebo</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>HR (95% CI):</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.82 (0.73, 0.92)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; <strong>P-value:</strong>&nbsp;&nbsp; 0.0008</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p>Dapagliflozin</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p>Placebo</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>Patients with event (%)</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>Patients at risk</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p>Dapagliflozin:<br />Placebo:</p></td></tr></tbody></table><p dir="ltr"><br /><br />An urgent heart failure visit was defined as an urgent, unplanned, assessment by a physician, e.g. in an Emergency Department, and requiring treatment for worsening heart failure (other than just an increase in oral diuretics).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients at risk is the number of patients at risk at the beginning of the period.</p><p dir="ltr">&nbsp;</p><p dir="ltr">All three components of the primary composite endpoint individually contributed to the treatment effect (Figure&nbsp;6).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Figure 6: Treatment effects for the primary composite endpoint and its components</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr"><br />An urgent heart failure visit was defined as an urgent, unplanned, assessment by a physician, e.g. in an Emergency Department, and requiring treatment for worsening heart failure (other than just an increase in oral diuretics).</p><p dir="ltr">The number of first events for the single components are the actual number of first events for each component and does not add up to the number of events in the composite endpoint.</p><p dir="ltr">Event rates are presented as the number of subjects with event per 100 patient years of follow-up.</p><p dir="ltr">p-values for single components are nominal. Cardiovascular death, here presented as a component of the primary endpoint, was also tested under formal Type&nbsp;1 error control as a secondary endpoint.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Dapagliflozin was superior to placebo in reducing the total number of heart failure events (first and recurrent hospitalisation for heart failure or urgent heart failure visits) and cardiovascular death; there were 815&nbsp;events in the dapagliflozin group versus 1057&nbsp;events in the placebo group (Rate Ratio&nbsp;0.77 [95%&nbsp;CI 0.67, 0.89]; p=0.0003).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The treatment benefit of dapagliflozin over placebo on the primary endpoint was observed across subgroups of patients with LVEF &le;&nbsp;49%, 50&ndash;59%, and &ge;&nbsp;60%. Effects were also consistent across other key subgroups categorised by e.g. age, gender, NYHA class, NT-proBNP level, subacute status, and type&nbsp;2 diabetes mellitus status.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Patient reported outcome &ndash; heart failure symptoms</em></p><p dir="ltr">Treatment with dapagliflozin resulted in a statistically significant benefit over placebo in heart failure symptoms, as measured by change from baseline at month&nbsp;8 in the KCCQ-TSS, (Win Ratio&nbsp;1.11 [95% CI 1.03, 1.21]; p=0.0086). Both symptom frequency and symptom burden contributed to the results.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In responder analyses, clinically meaningful deterioration, defined as 5&nbsp;points or more, was lower for the dapagliflozin treatment group compared with placebo. The benefit observed with dapagliflozin remained when applying a more conservative cut-off. The proportion of patients with a clinically meaningful improvement on the KCCQ-TSS from baseline at 8&nbsp;months did not differ between treatment groups (Table&nbsp;11).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table&nbsp;11. Number and percent of patients with clinically meaningful deterioration and improvement on the KCCQ-TSS at 8 months</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:605px"><tbody><tr><td><p><strong>Change from baseline at 8&nbsp;months:</strong></p></td><td style="vertical-align:top"><p><strong>Dapagliflozin<br />10 mg</strong></p><p><strong>n<sup>a</sup>=1316</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>n<sup>a</sup>=1311</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Deterioration</em></strong></p></td><td style="vertical-align:top"><p><strong>n (%) deteriorated<sup>b</sup></strong></p></td><td style="vertical-align:top"><p><strong>n (%) deteriorated<sup>b</sup></strong></p></td><td style="vertical-align:top"><p><strong>Odds ratio<sup>c</sup> (95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>p-value</strong></p></td></tr><tr><td style="vertical-align:top"><p>&ge; 5 points (moderate deterioration)</p></td><td style="vertical-align:top"><p>264 (24.1)</p></td><td style="vertical-align:top"><p>317 (29.1)</p></td><td style="vertical-align:top"><p>0.78<br />(0.64, 0.95)</p></td><td style="vertical-align:top"><p>0.0127</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 14 points (large deterioration)</p></td><td style="vertical-align:top"><p>148 (13.5)</p></td><td style="vertical-align:top"><p>201 (18.4)</p></td><td style="vertical-align:top"><p>0.70<br />(0.55, 0.88)</p></td><td style="vertical-align:top"><p>0.0026</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Improvement</em></strong></p></td><td style="vertical-align:top"><p><strong>n (%) improved<sup>d</sup></strong></p></td><td style="vertical-align:top"><p><strong>n (%) improved<sup>d</sup></strong></p></td><td style="vertical-align:top"><p><strong>Odds ratio<sup>e</sup> (95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>p-value</strong><strong><sup>f</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&ge; 13 points (small to moderate improvement)</p></td><td style="vertical-align:top"><p>531 (48.4)</p></td><td style="vertical-align:top"><p>498 (45.6)</p></td><td style="vertical-align:top"><p>1.13<br />(0.95, 1.33)</p></td><td style="vertical-align:top"><p>0.1608</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 17 points (large improvement)</p></td><td style="vertical-align:top"><p>486 (44.3)</p></td><td style="vertical-align:top"><p>478 (43.8)</p></td><td style="vertical-align:top"><p>1.06<br />(0.89, 1.26)</p></td><td style="vertical-align:top"><p>0.5137</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a </sup>Number of patients with an observed KCCQ-TSS or who died prior to 8&nbsp;months. Number includes patients with an 8‑month assessment (Visit&nbsp;5) planned or performed prior to 11&nbsp;March&nbsp;2020, when COVID-19 was declared a pandemic by the WHO. Data for patients with planned but not performed assessment prior to 11&nbsp;March&nbsp;2020 was imputed.</p><p><sup>b</sup> Number of subjects who died prior to the given time point or had an observed deterioration from baseline equal to or exceeding the given threshold. Patients with a KCCQ-TSS at baseline which was too low to possibly experience a deterioration were defined as deteriorated if their score at 8 months was not higher than baseline.</p><p><sup>c</sup> For deterioration, an odds ratio &lt;1 favours dapagliflozin 10 mg.</p><p><sup>d</sup> Number of subjects who had an observed improvement of at least 13 or 17 points from baseline. Patients who died prior to the given timepoint are counted as not improved. Patients with a KCCQ-TSS at baseline which was too high to possibly experience an improvement were defined as improved if their score at 8 months was not lower than baseline.</p><p><sup>e</sup> For improvement, an odds ratio &gt;1 favours dapagliflozin 10 mg.</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Heart failure across DAPA-HF and DELIVER studies</u></em></p><p dir="ltr">In a pooled analysis of DAPA-HF and DELIVER, the treatment effect of dapagliflozin on the composite endpoint of cardiovascular death, hospitalisation for heart failure or urgent heart failure visit was consistent across the LVEF range (Figure&nbsp;7).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Figure 7: Treatment effect for the primary composite endpoint by baseline LVEF</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">&nbsp;</p><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p>Number of patients&nbsp;&nbsp;&nbsp;&nbsp; 11007</p><p>Mean LVEF (%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 44.20</p><p>Standard deviation&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13.94</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>LVEF (%)</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>Hazard Ratio</strong></p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">Definitions of the primary endpoints from each study are used. In DAPA-HF the primary endpoint included death with undetermined cause of death. In DELIVER the primary endpoint did not include death with undetermined cause of death.</p><p dir="ltr">Data for LVEF between 15% and 75% are presented in the figure. At baseline; 0.5% of patients had LVEF&nbsp;&lt;&nbsp;15% and 0.7% had LVEF&nbsp;&gt;&nbsp;75%.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In a pre-specified subject level pooled analysis of the DAPA-HF and DELIVER studies, dapagliflozin compared with placebo reduced the risk of cardiovascular death (HR&nbsp;0.85 [95%&nbsp;CI&nbsp;0.75, 0.96], p=0.0115) (Figure&nbsp;8). Both studies contributed to the effect.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Figure 8: Time to first occurrence of cardiovascular death (pooled analysis of DAPA-HF and DELIVER studies)</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">&nbsp;</p><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>Patients with event (%)</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>Months from randomisation</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>HR (95% CI):</strong>&nbsp; 0.85 (0.75, 0.96)&nbsp;&nbsp;&nbsp;&nbsp; <strong>P-value:</strong>&nbsp; 0.0115</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>Dapagliflozin vs. Placebo</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p>Dapagliflozin</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p>Placebo</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>Patients at risk:</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p>Dapagliflozin:<br />Placebo:</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr"><br />Definitions of CV death from each study is used. In DAPA-HF, CV death included death with undetermined cause of death. In DELIVER, CV death did not include death with undetermined cause of death.</p><p dir="ltr">Patients at risk is the number of patients at risk at the beginning of the period.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Chronic kidney disease</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">The Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD) was&nbsp;an international, multicentre, randomised, double-blind, placebo-controlled study in patients with chronic kidney disease (CKD) with eGFR&nbsp;&ge;&nbsp;25 to &le;&nbsp;75 mL/min/1.73&nbsp;m<sup>2</sup> and albuminuria (urine albumin creatinine ratio [UACR] &ge;&nbsp;200 and &le;&nbsp;5000 mg/g) to determine the effect of dapagliflozin compared with placebo, when added to background standard of care therapy, on the incidence of the composite endpoint of &ge;&nbsp;50%&nbsp;sustained decline in eGFR, end-stage kidney disease (ESKD) (defined as sustained eGFR&nbsp;&lt;&nbsp;15&nbsp;mL/min/1.73 m<sup>2</sup>, chronic dialysis treatment or receiving a renal transplant), cardiovascular or renal death.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Of 4,304 patients, 2,152 were randomised to dapagliflozin 10 mg and 2,152 to placebo and followed for a median of 28.5 months. Treatment was continued if eGFR fell to levels below&nbsp;25&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> during the study and could be continued in cases when dialysis was needed.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The mean age of the study population was 61.8&nbsp;years, 66.9% were male. At baseline, mean eGFR was 43.1&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> and median UACR was&nbsp;949.3&nbsp;mg/g, 44.1% of patients had eGFR&nbsp;30 to &lt;&nbsp;45&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> and 14.5% had eGFR &lt;&nbsp;30 mL/min/1.73&nbsp;m<sup>2</sup>. 67.5% of the patients had type 2 diabetes mellitus. Patients were on standard of care (SOC) therapy; 97.0% of patients were treated with an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Dapagliflozin was superior to placebo in preventing the primary composite endpoint of &ge;&nbsp;50% sustained decline in eGFR, reaching end-stage kidney disease, cardiovascular or renal death (HR&nbsp;0.61&nbsp;[95% CI 0.51, 0.72]; p&nbsp;&lt;&nbsp;0.0001). The number needed to treat per 27 months was 19&nbsp;(95%&nbsp;CI 15, 27). Based on the Kaplan-Meier plot, the dapagliflozin and placebo event curves began to separate early (4 months) and continued to diverge over the study period (Figure 9).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Figure 9: Time to first occurrence of the primary composite endpoint, &ge;&nbsp;50% sustained decline in eGFR, end-stage kidney disease, cardiovascular or renal death</strong></p><p dir="ltr">&nbsp;</p><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>Patients with event (%)</strong></p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>Months from randomisation</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p>Dapagliflozin</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p>Placebo</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>Patients at risk</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p>Placebo:</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p>Dapagliflozin:</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>P-</strong><strong>value</strong><strong>:</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>HR (95%CI):</strong></p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">Patients at risk is the number of patients at risk at the beginning of the period.</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr">All four components of the primary composite endpoint individually contributed to the treatment effect. Dapagliflozin also reduced the incidence of the composite endpoint of &ge;&nbsp;50% sustained decline in eGFR, end-stage kidney disease or renal death (HR&nbsp;0.56&nbsp;[95%&nbsp;CI&nbsp;0.45,&nbsp;0.68], p&lt;0.0001) and the composite endpoint of cardiovascular death and hospitalisation for heart failure (HR&nbsp;0.71&nbsp;[95%&nbsp;CI&nbsp;0.55,&nbsp;0.92], p=0.0089) (Figure 10).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Figure&nbsp;10: Treatment effects for the primary and secondary composite endpoints, their individual components, and all-cause mortality</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">The number of first events for the single components are the actual number of first events for each component and does not add up to the number of events in the composite endpoint.</p><p dir="ltr">Event rates are presented as the number of subjects with event per 100 patient years of follow-up.</p><p dir="ltr">Hazard ratio estimates are not presented for subgroups with less than 15 events in total, both arms combined.</p><p dir="ltr">p-values for components of the composite endpoints are nominal.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">Treatment with dapagliflozin improved overall survival in chronic kidney disease patients with a significant reduction in all-cause mortality (HR&nbsp;0.69&nbsp;[95%&nbsp;CI&nbsp;0.53,&nbsp;0.88], p=0.0035) (Figure 11).</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Figure&nbsp;11: </strong><strong>Time to first occurrence of death from any cause</strong></p><p dir="ltr">&nbsp;</p><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>P-</strong><strong>value</strong><strong>:</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>HR (95%CI):</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p>Placebo</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p>Dapagliflozin</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>Patients with event (%)</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p>Placebo:</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p>Dapagliflozin:</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>Patients at risk</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>Months from randomisation</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p><strong>Dapagliflozin vs. Placebo</strong></p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">Patients at risk is the number of patients at risk at the beginning of the period.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The treatment effect of dapagliflozin was consistent in chronic kidney disease patients with type&nbsp;2 diabetes mellitus and without diabetes (Figure 12).</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Figure&nbsp;12: Treatment effects in patients with type 2 diabetes mellitus and in patients without</strong></p><p dir="ltr"><strong>diabetes</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">The number of first events for the single components are the actual number of first events for each component and does not add up to the number of events in the composite endpoint.</p><p dir="ltr">Hazard ratio estimates are not presented for subgroups with less than 15 events in total, both arms combined.</p><p dir="ltr">Event rates are presented as the number of subjects with event per 100 patient years of follow-up.</p><p dir="ltr">p-values are nominal.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The treatment benefit of dapagliflozin over placebo on the primary endpoint was also consistent across other key subgroups, including eGFR and UACR levels, age, gender, and region.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Treatment with dapagliflozin led to a greater reduction in albuminuria. The effect was observed as early as 14&nbsp;days and was maintained throughout the study. At 36 months, the adjusted mean percent change from baseline in UACR&nbsp;(mg/g) was ‑41% in patients treated with dapagliflozin and ‑20% in patients treated with placebo, with a difference between treatment groups of ‑26.3% ([95%&nbsp;CI&nbsp;‑36.8,&nbsp;‑14.0], nominal p=0.0001).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The incidence of doubling of serum creatinine since the most recent laboratory measurement (an evaluation of acute worsening in renal function), was reduced in the dapagliflozin group compared with the placebo group (HR&nbsp;0.68&nbsp;[95%&nbsp;CI&nbsp;0.49,&nbsp;0.94], nominal p=0.0187).</p><p dir="ltr">&nbsp;</p><p dir="ltr">There were fewer patients with renal-related adverse events in the dapagliflozin group compared with the placebo group, 144&nbsp;(6.7%) and 169&nbsp;(7.9%) in the dapagliflozin and placebo groups, respectively.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Paediatric population</p><p dir="ltr">&nbsp;</p><p dir="ltr">Pharmacokinetics in the pediatric population have not been studied</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Absorption</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Dapagliflozin was rapidly and well absorbed after oral administration. Maximum dapagliflozin plasma concentrations (C<sub>max</sub>) were usually attained within 2&nbsp;hours after administration in the fasted state. Geometric mean steady-state dapagliflozin C<sub>max</sub> and AUC<sub>&tau;</sub> values following once daily 10&nbsp;mg doses of dapagliflozin were 158&nbsp;ng/mL and 628&nbsp;ng&nbsp;h/mL, respectively. The absolute oral bioavailability of dapagliflozin following the administration of a 10&nbsp;mg dose is 78%. Administration with a high-fat meal decreased dapagliflozin C<sub>max</sub> by up to 50% and prolonged T<sub>max</sub> by approximately 1&nbsp;hour, but did not alter AUC as compared with the fasted state. These changes are not considered to be clinically meaningful. Hence, Forxiga can be administered with or without food.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Distribution</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Dapagliflozin is approximately 91% protein bound. Protein binding was not altered in various disease states (e.g. renal or hepatic impairment). The mean steady‑state volume of distribution of dapagliflozin was 118&nbsp;liters.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Biotransformation</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Dapagliflozin is extensively metabolised, primarily to yield dapagliflozin&nbsp;3‑O‑glucuronide, which is an inactive metabolite. Dapagliflozin&nbsp;3‑O‑glucuronide or other metabolites do not contribute to the glucose‑lowering effects. The formation of dapagliflozin&nbsp;3‑O‑glucuronide is mediated by UGT1A9, an enzyme present in the liver and kidney, and CYP‑mediated metabolism was a minor clearance pathway in humans.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Elimination</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The mean plasma terminal half‑life&nbsp;(t<sub>1/2</sub>) for dapagliflozin was 12.9&nbsp;hours following a single oral dose of dapagliflozin&nbsp;10&nbsp;mg to healthy subjects. The mean total systemic clearance of dapagliflozin administered intravenously was 207&nbsp;mL/min. Dapagliflozin and related metabolites are primarily eliminated via urinary excretion with less than 2% as unchanged dapagliflozin. After administration of a 50&nbsp;mg [<sup>14</sup>C]‑dapagliflozin dose, 96% was recovered, 75% in urine and 21% in faeces. In faeces, approximately 15% of the dose was excreted as parent drug.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Linearity</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Dapagliflozin exposure increased proportional to the increment in dapagliflozin dose over the range of 0.1&nbsp;to&nbsp;500&nbsp;mg and its pharmacokinetics did not change with time upon repeated daily dosing for up to 24&nbsp;weeks.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Special populations</u></p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Renal impairment</u></em></p><p dir="ltr">At steady‑state (20&nbsp;mg once‑daily dapagliflozin for 7&nbsp;days), subjects with type&nbsp;2 diabetes mellitus and mild, moderate or severe renal impairment (as determined by iohexol plasma clearance) had mean systemic exposures of dapagliflozin of 32%, 60% and 87% higher, respectively, than those of subjects with type&nbsp;2 diabetes mellitus and normal renal function. The steady‑state 24‑hour urinary glucose excretion was highly dependent on renal function and 85, 52, 18 and 11&nbsp;g of glucose/day was excreted by subjects with type&nbsp;2 diabetes mellitus and normal renal function or mild, moderate or severe renal impairment, respectively. The impact of haemodialysis on dapagliflozin exposure is not known. The effect of reduced renal function on systemic exposure was evaluated in a population pharmacokinetic model. Consistent with previous results, model predicted AUC was higher in patients with chronic kidney disease compared with patients with normal renal function, and was not meaningfully different in chronic kidney disease patients with type 2 diabetes mellitus and without diabetes.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Hepatic impairment</u></em></p><p dir="ltr">In subjects with mild or moderate hepatic impairment (Child-Pugh classes&nbsp;A and B), mean C<sub>max</sub> and AUC of dapagliflozin were up to 12% and 36% higher, respectively, compared to healthy matched control subjects. These differences were not considered to be clinically meaningful. In subjects with severe hepatic impairment (Child‑Pugh&nbsp;class&nbsp;C) mean C<sub>max</sub> and AUC of dapagliflozin were 40% and 67% higher than matched healthy controls, respectively.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Elderly (&ge;&nbsp;65&nbsp;years)</u></em></p><p dir="ltr">There is no clinically meaningful increase in exposure based on age alone in subjects up to 70&nbsp;years&nbsp;old. However, an increased exposure due to age-related decrease in renal function can be expected. There are insufficient data to draw conclusions regarding exposure in patients &gt;&nbsp;70&nbsp;years&nbsp;old.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Paediatric population</u></em></p><p dir="ltr">Pharmacokinetics in the paediatric population have not been studied</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Gender</u></em></p><p dir="ltr">The mean dapagliflozin AUC<sub>ss</sub> in females was estimated to be about 22% higher than in males.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Race</u></em></p><p dir="ltr">There were no clinically relevant differences in systemic exposures between White, Black or Asian races.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Body weight</u></em></p><p dir="ltr">Dapagliflozin exposure was found to decrease with increased weight. Consequently, low‑weight patients may have somewhat increased exposure and patients with high weight somewhat decreased exposure. However, the differences in exposure were not considered clinically meaningful.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Non‑clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and fertility. Dapagliflozin did not induce tumours in either mice or rats at any of the doses evaluated in two‑year carcinogenicity studies.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Reproductive and developmental toxicity</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Direct administration of dapagliflozin to weanling juvenile rats and indirect exposure during late pregnancy (time periods corresponding to the second and third trimesters of pregnancy with respect to human renal maturation) and lactation are each associated with increased incidence and/or severity of renal pelvic and tubular dilatations in progeny.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In a juvenile toxicity study, when dapagliflozin was dosed directly to young rats from postnatal day&nbsp;21 until postnatal day&nbsp;90, renal pelvic and tubular dilatations were reported at all dose levels; pup exposures at the lowest dose tested were &ge;&nbsp;15&nbsp;times the maximum recommended human dose. These findings were associated with dose-related increases in kidney weight and macroscopic kidney enlargement observed at all doses. The renal pelvic and tubular dilatations observed in juvenile animals did not fully reverse within the approximate 1‑month recovery period.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In a separate study of pre- and postnatal development, maternal rats were dosed from gestation day&nbsp;6 through postnatal day&nbsp;21, and pups were indirectly exposed <em>in utero</em> and throughout lactation. (A satellite study was conducted to assess dapagliflozin exposures in milk and pups.) Increased incidence or severity of renal pelvic dilatation was observed in adult offspring of treated dams, although only at the highest dose tested (associated maternal and pup dapagliflozin exposures were 1,415&nbsp;times and 137&nbsp;times, respectively, the human values at the maximum recommended human dose). Additional developmental toxicity was limited to dose-related reductions in pup body weights, and observed only at doses &ge;&nbsp;15&nbsp;mg/kg/day (associated with pup exposures that are &ge;&nbsp;29&nbsp;times the human values at the maximum recommended human dose). Maternal toxicity was evident only at the highest dose tested, and limited to transient reductions in body weight and food consumption at dose. The no observed adverse effect level (NOAEL) for developmental toxicity, the lowest dose tested, is associated with a maternal systemic exposure multiple that is approximately 19&nbsp;times the human value at the maximum recommended human dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In additional studies of embryo‑foetal development in rats and rabbits, dapagliflozin was administered for intervals coinciding with the major periods of organogenesis in each species. Neither maternal nor developmental toxicities were observed in rabbits at any dose tested; the highest dose tested is associated with a systemic exposure multiple of approximately 1,191&nbsp;times the maximum recommended human dose. In rats, dapagliflozin was neither embryolethal nor teratogenic at exposures up to 1,441&nbsp;times the maximum recommended human dose.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Tablet core</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Microcrystalline cellulose (E460i)</p><p dir="ltr">Lactose</p><p dir="ltr">Crospovidone (E1202)</p><p dir="ltr">Silicon dioxide (E551)</p><p dir="ltr">Magnesium stearate (E470b)</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Film‑coating</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Polyvinyl alcohol (E1203)</p><p dir="ltr">Titanium dioxide (E171)</p><p dir="ltr">Macrogol&nbsp;3350 (E1521)</p><p dir="ltr">Talc (E553b)</p><p dir="ltr">Iron oxide yellow (E172)</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">This medicinal product does not require any special storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Alu/Alu blister<br />Pack size of 28 film-coated tablets in non-perforated calendar blisters<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AstraZeneca UK Limited,
600 Capability Green,
Luton,
LU1 3LU,
UK.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dec 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>